Novel Kinetic Solution-Based Separation Approaches for Small Molecule Drug Discovery by Bao, Jiayin
	  NOVEL KINETIC SOLUTION-BASED SEPARATION 
APPROACHES FOR SMALL MOLECULE DRUG 
DISCOVERY 
 
 
 
JIAYIN BAO 
 
 
 
A DISSERTATION SUBMITTED TO 
THE FACULTY OF GRADUATE STUDIES 
IN PARTIAL FULFILLMENT OF THE REQUIREMENTS 
FOR THE DEGREE OF 
DOCTOR OF PHILOSOPHY 
 
 
 
GRADUATE PROGRAM IN CHEMISTRY 
YORK UNIVERSITY 
TORONTO, ONTARIO 
 
 
January 2017 
 
 
© Jiayin Bao, 2017 
 
 
 
 
 
	  	  
	  ii 
ABSTRACT 	  
The modern pharmaceutical industry has achieved remarkable successes in medicinal 
chemistry. However, many diseases are incurable due to the difficulty of finding new drugs. De 
novo drug discovery contains two steps: the primary screening focuses on selecting protein 
(target) binding drug (ligand); the secondary screening concentrates on calculating kinetic 
binding parameters of target-ligand complex.  Conventional methods for the primary screening 
are typically surface-based, which suffer intensely from nonspecific interactions; the existing 
methods for secondary screening are either affinity-based or require surface immobilization, both 
cannot accurately calculate kinetic binding parameters. Hence, this research focuses on the 
development of the solution-based kinetic platform that facilitates both primary and secondary 
screenings. We combined kinetic capillary electrophoresis (KCE) with DNA-encoded ligand 
(DEL) technology to build a solution-based platform for primary screening of ligands. KCE 
offers high partitioning efficiency but requires the knowledge of electrophoretic mobility of 
target-ligand complex, and thus, we developed a mathematical model to predict electrophoretic 
mobility of target-DEL complex. This model was tested by using the targets interacted with 18 
artificial DELs that contain various combinations of dsDNA and ssDNA regions, together with 2 
DELs manufactured by GlaxoSmithKline. The results confirmed the precision, accuracy, and 
ruggedness of our model. This model will facilitate the reliable use of KCE-DEL based primary 
screening. Next, we developed a kinetic size-exclusion chromatography-mass spectrometry 
(KSEC-MS) as the label-free solution-based platform for calculating kinetic binding parameters 
of target-ligand interactions in secondary screening. KSEC-MS employs size-exclusion 
chromatography to separate small molecule ligand from protein target-ligand complex without 
immobilization and mass spectrometry to detect small molecule without a label. The rate 
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constants of complex formation and dissociation are calculated from the temporal ligand 
concentration profile. Methods of KSEC-MS have been developed by using 2 proteins with the 
corresponding drugs. The resulted kinetic and affinity binding parameters were validated, which 
confirmed the precision and accuracy of KSEC-MS. We foresee that the KSEC-MS will become 
a universal approach for the kinetic analysis of target-ligand interactions in secondary screening. 
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CHAPTER 1: NTRODUCTION TO ANALYSIS OF PROTEIN-
SMALL MOLECULE INTERACTIONS 
1.1 Overview  
The history of pharmaceutical development can be divided intro three eras. The first drug 
based therapies originated from the 19th mainly came from natural sources and treatments relied 
on serendipity. The majority of natural compounds were administered without sufficient 
knowledge of toxicity; therefore, these compounds often failed to serve as useful therapeutics 
[1]. At the beginning of the 20th century, the modern pharmaceutical industry began to use a 
variety of new, innovative technologies. For instance, the advancement of X-ray crystallography 
[2], as well as NMR technologies [3], allowed scientists to study the chemical structures of many 
therapeutic agents. The birth of recombinant DNA technology [4] facilitated the development of 
protein-based drug targets. Also, the progression in synthetic chemistry, high throughput 
screening (HTS), as well as computer-based molecular modeling significantly enhanced the 
screening measures of pharmaceutical agents. Entering the 21st century, the initiation of “omics” 
technologies [5] greatly improved the identification of disease targets and also boosted the 
development of biopharmaceuticals. 
Despite these innovations and advances, modern pharmaceutical development still is a long 
and expensive process. On average, it takes 10-12 years from the initial research to final 
commercial product and costs approximately US$ 1-1.2 billion to develop a single drug [6]. The 
entire process of pharmaceutical discovery and development involves four major stages: drug 
discovery, pre-clinical development, clinical trial, and commercialization. The first stage, drug 
discovery starts with finding a disease-causing target. The disease-causing targets are commonly 
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referred to drug targets or biological targets. They are generally the proteins or gene sequences 
presented in the human body. In the process of drug discovery, the targets are usually used like 
baits to “lure out” binders from a large pool of ligands, a process typically referred to ligand 
screening. Ligand screening can be further divided intro primary and secondary screenings. The 
primary screening focuses on the preliminary selection of all target binders from highly 
populated combinatorial libraries, which typically contain 105 to 106 entities. Methods of HTS 
are usually engaged, which intend to select every binding ligand and rule out any non-binders 
with the highest efficiency. After primary screening, all selected binders are subjected to 
secondary screening, in which ligands are investigated by various analytical techniques. Affinity 
and kinetic parameters are calculated and utilized for ranking. Upon completing the stage of drug 
discovery, there are typically 103 potential leads generated before carrying into the next stage. 
The second stage is preclinical development, in which potential leads are further tested by 
extensive in vitro and in vivo assessments in combination with iterative modifications to 
optimize the pharmacodynamics, and pharmacokinetics. The third stage is the clinical trial, in 
which the potential drug candidates are given to human subjects with the dosage form and 
quantity intended for marketing. The human subjects range from healthy volunteers to patients 
with various illness levels. The drug efficacy and toxicity are extensively investigated in this 
stage; many potential leads failed here. The final stage is commercialization, in which the drug 
products are manufactured, and the application of a new drug has to be filed and approved by a 
regulatory agency such as the FDA. In addition, the post-approval studies are also conducted for 
monitoring the safety and performance of the commercialized drugs [7]. 
Although the modern pharmaceutical industry has grown for over a century, there are still 
many diseases untreated; likewise, despite the vast amount of known chemical and protein 
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structures, there are still very limited numbers of structurally different drugs. The Nobel prize-
winning J.W. Black once had a famous quote, “the most fruitful basis for the discovery of a new 
drug is to start with an old drug” [8]. For the past decades, research and development in 
pharmaceutical industry spent more than US$ 50 billion a year to pursue only a limited number 
of drug targets. Until now, only 10% of disease-related genes have been explored and developed 
in drug discovery campaigns; similarly, only 6% of drug products on market today are 
structurally unique [9]. All this information leads to the fact that discovering the new drugs 
becomes the Holy Grail in today’s pharmaceutical industry.  
However, identification of novel small molecule ligands remains a practical burden in drug 
discovery. Conventional methods for ligands screening are inadequate by definition: these 
methods either suffer intensely from nonspecific interactions or cannot accurately calculate the 
true kinetic parameters. Therefore, our research focuses on the development of tool sets that 
contain novel homogeneous solution-based kinetic approaches, which can be used to facilitate 
both primary and secondary screenings with highest efficiency and accuracy that beyond the 
stretch of existing methods.  
 
1.2 Targets, Ligands, and Target-Ligand Interactions 
 
1.2.1 Drug Targets 
The process of modern drug discovery starts with the identification of disease-causing 
targets. Disease targets are usually mutant or native proteins from either human body or any 
parasitic organism, and their functions can be modified upon interacting with the therapeutic 
agents. While there are multiple ways of finding new targets, research scientists generally follow 
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two main approaches. Analysis of pathophysiology is a safe and logical approach. This method 
starts with an understanding of the biochemical pathway that is responsible for the disease 
phenotype. Afterward, it verifies the particular biochemical step that is amenable to therapeutic 
intervention. Finally, it selects the key molecule as the target. Alternatively, drug targets can be 
discovered through a backward procedure. This starts with the analysis of action mechanisms of 
existing drugs, and then search for the matching targets [7]. In 2006, a comprehensive survey 
conducted by Imming et al. indicated that there were 324 unique protein targets at the time, 266 
were human genome derived proteins and remainders came from pathogenic organisms such as 
bacteria, virus, and fungus [10]. Proteins and glycoproteins, such as enzymes, receptors, ion 
channels, transport proteins, and antibodies are the most common type of targets. Other disease-
causing molecules (for example, gene sequences and ribosomes) have also been discovered and 
pointed for therapeutic purposes. 
 
1.2.2 Small Molecules Ligands  
While there is no strict definition of small molecules, they usually are low molecular 
weight (less than 1,500 Da) organic molecules [11]. Small molecules are extremely powerful 
tools as they can quickly penetrate through cell membranes, bind to targets, initiate biomolecular 
interactions, and then manipulate corresponding biochemical processes. The survey as mentioned 
earlier published by Imming et al. revealed that by 2006, there were 1357 unique drugs, 1204 of 
these were small molecules and 166 were biotherapeutic agents [10]. Thus, most of the available 
drugs on the market are small molecules. 
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1.2.2.1 The Ligand Library 
In general, small molecules can be obtained either from the natural sources or chemical 
synthesis. Natural products such as leaves, shoot, barks, roots, and even marine life forms 
contain massive amounts of bio-relevant chemical compounds, which have been exploited 
medicinally for millennia and they still serve as a valuable source of drugs in the modern 
pharmaceutical industry [2]. One of the most significant benefits of natural products is to 
diversify the chemical compositions of the existing chemical libraries. However, due to 
difficulties in sourcing, isolating and identifying bioactive components, production of highly 
populated natural products library is impractical. Also, analysis and chemical modification of 
these incredibly complex structures are also time consuming and labor intensive. Therefore, 
chemical synthesis is considered the most practical approach in manufacturing highly populated 
small molecule libraries.  
Methods of small molecule synthesis can be either target-oriented or diversity-oriented 
[11]. In target-oriented synthesis, compounds structures are deliberately created to interact with 
the targets. Accordingly the knowledge of target structures and rational designs are engaged. 
Diversity-oriented synthesis, on the other hand, aims to maximize the structural diversity without 
consideration of target structures. The choice is case dependent. For instance, in occasions when 
dealing with the well-defined targets, the rational design approach is often desirable, in 
particular, if the structures of nature ligands of such targets are known. Alternatively, when the 
character of the disease is not well understood, and neither the target nor the ligand was 
previously established, rational design becomes unrealistic; thus, diversity-oriented synthesis 
would be the only option.  
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1.2.2.2 DNA-Encoded Chemical Libraries 
Conventional methods for selecting target-binding ligands require high throughput 
screening of highly populated small molecule libraries, which typically cover up to few million 
compounds. In HTS, the ligands are usually selected based on their affinity interactions with the 
target. Sample concentrations can profoundly influence affinity interactions; as a general rule, 
affinity binding interactions should be conducted with the sample concentration levels at the 
range of equilibrium dissociation constant Kd. Therefore, high-affinity ligands are usually present 
in low concentrations, which are tough to isolate and identify.  
In contrast to small molecules, identification of biopolymers such as DNA and RNA can be 
successfully and elegantly accomplished even with very low concentrations. Various display 
technologies have been developed to achieve the identifications of biopolymer-attached ligands 
to targets; examples include phage display, yeast display, ribosome display, as well as mRNA 
display. Inspired by display technologies, in 1992, Brenner and Lerner [12, 13] introduced the 
concept of associating DNA-based barcode tag with synthetic peptides. Since then, numerous 
strategies have been implemented for constructing the DNA-encoded ligand (DEL) libraries. 
Methods of DEL libraries constructions can be mostly classified into two main types. The first 
type relies on stepwise split-and-pool of multi-step building block assembly, with parallel DNA 
coding fragments [14]. Such approaches have been widely developed and applied by 
GlaxoSmithKline (GSK), X-Chem, Nuevolution, and Philochem. The second type is based on 
DNA-templated synthesis. Pavel Sergeev first introduced the original concept of nucleic acid 
template chemical synthesis, in which the corresponding DNA-fragment tags hybrid and brought 
chemically active groups close together, thus, promoting chemical reactions. This approach 
allows very specific chemical reaction and bypasses the need for using the chemical protecting 
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groups. DNA-templated synthesis is a popular method for the production of DEL libraries and 
has been extensively applied by Ensemble Therapeutics, and Vipergen [11].  
 
1.2.3 Target-Ligand Interactions 
The potency of any therapeutic agent relies greatly on binding properties towards the 
corresponding disease target. The binding interactions between targets and ligands are either 
covalent or non-covalent. Covalent bonds are strong, being formed between interacting pairs of 
atoms through sharing of electrons. Although covalent drugs have proved to be potent 
therapeutics, due to the safety concerns, they are rarely considered when initiating a drug 
discovery process. Pharmaceutical companies fear that covalent drugs were so reactive and 
permanently bound to the wrong targets leading to toxicity [15]. In most cases, the 
pharmaceutical industry has, by all means, avoided development of drugs that commit to 
“marriage” and instead pursues “dating” as the mode of interaction. Alternatively, non-covalent 
drugs can form affinity interactions with the protein targets. The attraction forces in non-covalent 
interactions are commonly formed through hydrogen bonding, van der Waals forces, and 
hydrophobic effects [1].  
 
1.2.3.1 Non-Covalent Target-Ligand Interactions 
In biological systems, most of the biomolecular interactions are governed by non-covalent 
interactions. Likewise, in modern pharmaceutical discovery, most of the drugs are designed to 
interact with disease target in a non-covalent fashion [10, 16]. Non-covalent interactions can be 
defined by:  
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on
off
T L T-L
k
k
⎯⎯⎯→+ ←⎯⎯
      (1-1) 
target (T) is typically a macromolecule such as protein or nucleic acid, the ligand (L) is a small 
molecule, and binding complex (T-L) is the product formed from interaction between T and L. 
Generally, the overall affinity or complex stability is defined by equilibrium dissociation 
constant Kd = koff/kon and a small Kd value refers to high binding affinity and complex stability. 
The kinetic rate constants koff and kon define the rate of complex dissociation and association 
respectively. Assessing the kinetic rate constants is critical in understanding the dynamics of 
non-covalent interactions between the target and ligand, which is also essential in determining 
drug efficacy and toxicity.   
 
1.2.3.2 Kinetics and Drug-Target Residence Time 
For more than a century, the molecular basis of target-ligand interactions has been 
predominantly judged by simple binding affinities; interactions between target and ligand were 
perceived as structural complimentary in static states. However, in the late 20th century, 
advancement in biophysical studies suggested that the target-ligand interactions are often 
achieved via adaptive structural changes, in a dynamic manner. Over the past two decades, 
various studies demonstrated that the durability and potency of drugs depend rather on the half-
life of target-ligand complex than simple overall complex affinity. Additionally, in the context of 
a biological system, the duration of pharmacological effect, or drug-target residence time, 
prominently depends on the temporal stability of the target-ligand binding complex. Ideally, in a 
closed (in vitro) system, where target and ligand concentrations stay constant, the drug-target 
residence time depends on the rate constants of both target-ligand association (kon) and 
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dissociation (koff). Conversely, in the case of open (in vivo) system, where active efflux 
consistently eliminating drug compounds, residence time primarily depends on rate constant of 
complex dissociation koff. Decisions of selecting desirable drug-target residence time become 
case dependent. Prolonged residence time often enhance the durability of pharmacological effect, 
however, might also cause the off-target toxicity [17]. Therefore, the quantitative assessments of 
kinetic rate constants are critical in understanding drug-target residence time, which is connected 
to the overall pharmacological and toxicological effects. 
 
1.3 Analytical Methods in Ligand Discovery 
In pharmaceutical development, the conventional analytical approaches can be generalized 
as surface-based or solution-based; each approach can be further defined as either affinity or 
kinetic method. Surface-based approaches comprise immobilization of targets or ligands onto 
sensor surface or stationary phase of the chromatography column. Given the extraordinary 
screening power, surface methods are a rule of thumb in primary screening. Examples of surface-
based affinity methods include protein microarray, small-molecule microarray, and affinity 
chromatography; there are also surface-based kinetic methods such as surface plasmon resonance 
(SPR) and biolayer interferometer (BLI). Compared to surface-based methods the solution-based 
approaches are relatively low throughput, as they typically require the purified/identified ligands 
to work with. However, solution-based methods are renowned for high precision and accuracy in 
calculating binding parameters, and thus often used in secondary screening. For example, the 
“gold standard” isothermal titration calorimetry (ITC) as well as electrospray ionization mass 
spectrometry (ESI-MS) are typically applied in determining the equilibrium dissociation constant 
Kd, and also in ranking binding affinities for various ligands against one target. Nevertheless, 
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each and every approach carries inherent systematic biases that often result in false negative or 
false positive outcomes. Therefore, the trail of analytical methodologies indeed determines the 
fate of drug discovery. 
 
1.3.1 Surface-based Affinity Methods 
Determining the binding affinities of non-covalent target-ligand interactions is important in 
understanding the therapeutic potencies of lead compounds. Identification of novel and potent 
ligand from the diverse chemical library is the heart in the early stage of drug discovery. The 
microarray technology was originated in 1991 when Fodor et al. introduced peptide microarray 
in their seminal work [18]. Significant development has been made over the past two decades, 
which makes microarray technology a robust and powerful tool in academia and industrial 
research. The applications of microarray technology cover virtually all types of biomolecules 
such as nucleic acids, proteins, small molecules, as well as live cells. Among all, protein 
microarray and small-molecule microarray have been implemented extensively in processes of 
HTS. 
Protein microarray is commonly applied in assessing the functions and activities of 
proteins on a large scale [19]. Protein microarray (often referred as functional protein 
microarray) was originally developed for systematic studies of protein bioactivities. Essentially, 
functional proteins are immobilized onto the optical surface through generic linkers such as His-
tag or GST-tag; followed by incubation with the fluorescently labeled ligands solution. Once 
reaching binding equilibrium, the bound ligands are retained while unbound ligands are 
partitioned out, and the fluorescent signals are recorded. Methods of protein microarray have 
been successfully applied in profiling various types of post-translational event, and also 
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assessing a variety of protein-protein interactions. Also, the latest high-content protein 
microarray allows simultaneous monitoring of bioactivities of thousands of proteins on a single 
chip, which significantly enhanced the performance of molecular profiling. Following the same 
concept, methods of protein microarray have also been applied as a promising HTS platform; 
numerous studies demonstrated the practicalities of this approach with binding affinities ranging 
from µM to nM.  
Small-molecule microarray played the significant role in the process of drug discovery 
[11]. However, unlike macromolecules such as protein and DNA, small-molecule 
immobilization is facing the obstacles of limited structural diversities and hindrance from 
immobilization. Various fabrication techniques have been developed to circumvent these 
limitations. For example, the non-covalent approaches by using DNA-directed/encoded ligand 
immobilization, or using the strong interactions between avidin-coated chips and biotin-labeled 
small-molecules. Alternatively, the ligand can be immobilized through covalent linkage to 
achieve a firm and stable bond between the ligands and array surface. Finally, the small-
molecule microarrays have also been fabricated via in situ chemical synthesis.  
The chemical libraries typically contain a vast number of compounds, which range from 
being achiral to racemic by nature. Screening and selecting of these synthetic racemic 
compounds is extremely critical in identifying biological activity as well as toxicities. The frontal 
affinity chromatography based approach with the combination of mass spectrometry detection 
has been developed for analyzing racemic chemical compounds [1]. In essence, the protein 
targets are immobilized on solid phase inside of column, followed by a solution of ligands 
flowing through the column to interact with targets. Each individual ligand has a distinctive 
eluate volume, which is often referred as the “breakthrough volume” and characterized as a 
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sigmoidal front. Frontal affinity chromatography [20] has been successfully applied to screen 
mixtures of chemical compounds against a wide range of biological targets. Also, this approach 
has also been implemented for analyzing binding affinity, such as determining Kd as well as 
ranking the relative binding affinities of ligand mixtures.  
 
1.3.2 Surface-based Kinetic Methods 
Surface-based kinetic methods have been extensively used in studying various 
biomolecular interactions. Optical biosensors such as SPR are ordinarily used as solid support for 
analyzing non-covalent target-ligand interactions [21]. Briefly, sample molecules, either targets 
or ligands, are covalently immobilized onto the gold surface. Gold is the common material for 
SPR surface sensor as it is highly stable against oxidation and widely compatible with various 
chemical linkages. The surface attachments of sample molecules impose particular angle in 
refractive index, which is described as SPR angle. As the binding occurs, the change of refractive 
index can be monitored using monochromatic light and measured in real time. The final data can 
be used to calculate the amount of bound analyte, binding affinity as well as the association and 
dissociation kinetic rate constants.  
BLI is a recently developed optical based method [22]. In essence, the sample molecules 
such as protein targets are immobilized onto the tip of an optic fibre; the molecular layer creates 
an interference pattern that can be identified. Next, the sample-attached optical fiber is 
submerged into the solution of ligands; binding of another layer of ligand molecules triggers the 
shift in the signatures of the interference pattern. Kinetic analysis of SPR and BLI are similar 
that the signals of association and dissociation are numerically fitted, and then kon and koff can be 
deconvoluted from the best fitting curves. The main advantages of surface-based techniques are 
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high sensitivities, little samples consumptions, and high-throughput. Also, these surface-based 
techniques are pure kinetic methods that rely only on numerical fitting for data processing; 
binding equilibrium is not required in assumptions and thus allowing the sample concentration of 
analytes surpass the range of binding affinity (Kd). Despite the renowned advantages, surface-
based methods inherently suffer from non-specific surface adsorption, which typically leads to 
false positive results during primary screening. In addition, the typical experimental setups 
require chemical immobilization of sample molecules onto the sensing surface, which often 
disturbs the molecular structures of either targets or ligands. Such disturbance in 3D structures 
can significantly affect the binding properties of the target-ligand interactions, which is 
detrimental in determining kinetic binding parameters. Thus, surface-based methods are not ideal 
for secondary screening. 
 
1.3.3 Solution-based Affinity Methods 
In the pharmaceutical industry, one of the most widely used solution-based affinity 
methods is ITC, which is also referred as “gold standard” in determining target-ligand binding 
affinity. In essence, ITC measures the time-resolved enthalpy change of the given target-ligand 
interactions [23]. The quantification of thermodynamic parameters such as enthalpy and entropy, 
affinity constant Kd, and even binding stoichiometry can be all achieved within a single ITC 
experiment. Furthermore, ITC can also be used for studying enzymatic kinetics to measure Kcat 
and KM [24]. Given its true label-free nature, ITC is considered as the method of choice for label-
free affinity studies as the analyzed binding parameters reflect the native binding states. 
However, there are also drawbacks: first, for heat changing measurements, to meet the limit of 
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detection relatively large amount of sample is often required; second, ITC cannot be used for 
kinetic analysis of non-covalent target-ligand interactions.  
Similarly, the conventional ESI-MS and nanoelectrospray ionization mass spectrometry 
(nESI-MS) have been widely adapted for studying non-covalent complexes [25, 26]. The simple 
ESI-MS and nESI-MS are considered as “snapshot” methods; essentially the ratio between the 
complexes and free ligands is recorded to calculate the equilibrium binding constant Kd. The 
main advantages of such approaches are:  (i) a single binding experiment is sufficient to estimate 
binding affinity; (ii) the minimum sample consumptions. As a result, ESI-MS and nESI-MS have 
been adopted in studying various target-ligand interactions. However, it is still a debate over the 
legitimacy of these methods that whether the detection of complexes in gas phase actually 
reflects the binding ratio in solution phase [27], as the process of ionization can trigger the 
complex dissociation; also, the ionization efficiencies may be different between the free 
molecule and binding complex. Finally, both ESI-MS and nESI-MS are affinity methods that 
cannot be used for kinetic analysis. Conclusively, all conventional label-free solution-based 
methods can be only used for affinity analysis, but cannot be used for studying the kinetics of 
target-ligand interactions. However, the kinetic parameters control the drug efficacy and toxicity 
in the human body. 
 
1.3.4 Solution-based Kinetic Methods 
Fluorescence-based bioanalytical assays are renowned for high sensitivity and convenient 
detection setups. However, such assays are often hindered by intrinsic fluorescence of 
compounds, present in highly populated libraries. Methods, like fluorescence polarization (FP) 
and time-resolved Förster resonance energy transfer (TR-FRET), are less affected by intrinsic 
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fluorescence of ligands during the process of screening [1]. Briefly, FP utilizes the depolarization 
of emission light to calculate the rate of molecular rotation of fluorescent ligand; the speed of 
rotation changes upon binding to the target, which offers the basis of target-ligand binding 
interactions. FRET is also a powerful technique and typically used for studying structures and 
dynamics of macromolecules. When two matching fluorophores are positioned in close 
proximity, the excited donor fluorophore transfers energy to the acceptor fluorophore and 
triggers its emission. Using the same principal, TR-FRET combines a long lifetime donor and a 
short lifetime acceptor to achieve time-resolved analysis of binding interactions.   
As previously discussed, labeling requires covalent modifications that can significantly 
affect the structures of targets or ligands as well as the binding properties. Therefore, labeled 
methods are not ideal for kinetic binding studies. Label-free methods, on the other hand, analyze 
the molecules without chemical modifications; thus the native states of interaction are 
maintained. Therefore, the solution-based kinetic methods are essential in both finding the target 
binding ligands and kinetic analysis of corresponding target-ligand interactions. Besides, for 
kinetic analysis, the label-free approaches are critical in determining the true kinetic parameters 
for target-ligand interactions.  
Kinetic capillary electrophoresis (KCE) is a conceptual platform, which contains a panel of 
methods that allow separating species to interact during capillary electrophoresis (CE) [28]. The 
concentration profiles of the interacting species are plotted over time, in which can be used to 
calculate both equilibrium and kinetic parameters. The basis of CE relies on the separation of 
species based on the differential charge to size ratios. Thus, KCE-based methods have been 
substantially adopted for kinetic analysis of protein-DNA interactions as well as DNA-aptamer 
selections. The detection during KCE-based protein-DNA studies is typically achieved through 
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fluorescent labeling of DNA molecules. For non-covalent target-ligand interaction studies, we 
have introduced two different types of KCE methods for label-free solution-based kinetic 
analyses: (i) kinetic capillary electrophoresis mass spectrometry (KCE-MS) and (ii) plug-plug 
kinetic capillary electrophoresis with UV detection (ppKCE-UV).  
 
1.3.4.1 Kinetic Capillary Electrophoresis with Mass Spectrometry Detection 
KCE-MS is a label-free solution based kinetic approach for analyzing interactions between 
protein (P) and small molecule (SM). The non-equilibrium capillary electrophoresis of 
equilibrium mixture (NECEEM) [28] was the method of choice for solution-based kinetic 
separation. Briefly, the P and SM were incubated to form an equilibrium mixture. The 
equilibrium mixture contained three distinct species: P, SM, and protein-small molecule complex 
P-SM. The equilibrium mixture was the sample of injection and during electrophoresis all three 
species separated from each other according to different charge to size ratios. The charge to size 
ratios between P and SM usually differ from each other. Thus they migrated into two distinct 
zones. However the charge to size ratios between P and P-SM are typically similar, thus they co-
migrated into a single zone. Also, during electrophoresis, SM separated from P-SM, which led to 
a disruption of equilibrium and triggered continues dissociation of P-SM. Such continues 
dissociation is typically featured as a “bridge” connecting the signals between SM and P-SM. 
Finally, the concentration profiles of SM were recorded over time and utilized in the subsequent 
kinetic calculations. One of the main advantages of NECEEM is that the signals from single 
specie are sufficient for calculating binding parameters. In this case, the signals from SM were 
recorded through the generic label-free mass spectrometry detection.  
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The procedure of KCE-MS [29] comprises two main parts (Figure 1.1): first part contains 
optimization and calibration (Step 1-3), and the second part provides measurements of binding 
parameters (Step 4-7). The first part, optimization and calibration, is a three-step task. Step 1, 
analyze and optimize the ESI-MS detection conditions of the pure small molecule ligand. Step 2, 
establish the serial dilution calibration curve of the ligand using the optimized detection 
conditions. Step 3, subject the protein target and small molecule ligand individually to determine 
the three fraction-collection windows (W1, W2, and W3) and complex migration time, tP⋅SM 
(used in koff calculation) using CE with UV light absorption detection. The second part, 
measurements of the binding parameters, is a four-step procedure. Step 4, an aliquot of the pre-
equilibrated protein-small molecule binding mixture is subjected for NECEEM. At the end of 
NECEEM, three fractions are collected according to pre-established fraction windows (W1, W2, 
and W3). As schematically illustrated in Figure 1.1B, W1 contains free SM in equilibrium 
mixture; W2 contains the SM that dissociated from the complex during NECEEM separation, and 
W3 contains the SM that is still within intact binding complexes.  
 
 
 
 
 
 
 
 
 
	  	  
	  18 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Schematic illustration of the practical realization of KCE-MS through off-line 
interfacing of NECEEM with ESI-TOF MS. Please see text for details. 
 
However, NECEEM uses in a physiological buffer, which is suitable for biomolecular 
interactions in CE experiments but incompatible with ESI-MS detections. Therefore, each 
collected fraction is desalted and dissolved in equal volumes of methanol (Step 5). In Step 6, the 
small molecule ligand concentrations in each fraction are determined by ESI-MS using the 
previously built calibration curve. Finally, in Step 7, the three concentrations are used to 
calculate Kd and koff with simple NECEEM formulas:  
    (1-2) 
	  	  
	  19 
    (1-3) 
where [SM]free,  [SM]dis,   and [SM]bound indicate the concentrations of free, dissociated, and 
bound SM in each fraction.  
 
1.3.4.2 Plug-plug Kinetic Capillary Electrophoresis with UV Detection 
KCE-UV is another label-free solution-based kinetic method that previously developed for 
analyzing DNA-small molecule interactions [30]. Besides, UV absorption is a generic, 
accessible, and practical means of detection: most molecules absorb light in UV, and all 
commercial CE instruments are equipped with UV absorption detection. The KCE method of 
choice is plug-plug kinetic capillary electrophoresis (ppKCE), which facilitates direct 
measurements of kinetic binding parameters kon and koff by first mixing and reacting molecules 
and then separating and dissociating the formed complexes. The concept of ppKCE-UV is 
schematically presented in Figure 1.2. At time zero, small plugs of A and B with concentrations 
of [A] and [B] and length of lA and lB, respectively, are sequentially injected one after another by 
a low-pressure pulse; the components with a lower mobility (e.g. A) is injected first. For 
examples, the slow moving DNA is A, which is injected first, and a small molecule B is injected 
later. Under the presence of a high electric field, both A and B are moved towards the outlet with 
different electrophoretic mobilities. When passing through each other, A and B form certain 
amount of interaction complex, C. The amount of formed complex is dependent on [A], [B], kon, 
and time of passage. When the zones of A or B is separated from that of C, C starts dissociating 
(the yellow curve illustrates the fitting of dissociation) with a rate depending on koff. A temporal 
propagation pattern of one component, for example, B is recorded by a UV detector placed at a 
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distance of L from the capillary inlet. The values of kon and koff can be determined by using the 
signal intensities of B and corresponding migration times from a ppKCE-UV electropherogram: 
      (1-4) 
     (1-5) 
Here It1 and It2 are signal intensities of B at times t1 and t2, respectively, in the exponential region 
of the trace (shown by the yellow line in Figure 1.2, bottom curve). The migration times of A, B, 
and C are represented by tA, tB, and tC, where tA = tC since the complex co-migrates with the 
DNA. Parameter ε is determined by solving the following non-explicit equation: 
  (1-6) 
In the above equations, Bfr is the area of the peak corresponding to unbound ligand. The Btot 
represents the integration of total amount of ligand, which is usually measured in a separate 
experiment with ligand injection only. lA and lB are the injection plug lengths of A and B. The 
other parameters have been defined above. The kinetic rate constant of complex dissociation, koff, 
can be determined by fitting the experimental decay curve.  
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Figure 1.2. Schematic illustration of the ppKCE method. Please see text for details. 
 
Although proven to be robust separation tools, KCE methods alone are not ideal for 
analyzing protein-small molecule interactions. The separation power of KCE methods depends 
on the differential charge to size ratios. However, neither protein nor small molecule is highly 
charged. Methods of KCE, in this case, are not generic separation tools meaning that 
optimizations are always required for each and every binding pair. Therefore, novel ligand 
screening methods are still in demand to achieve the solution-based high throughput primary 
screening; as well as the label-free solution-based kinetic methods for secondary screening.  
In this dissertation, we are going to introduce a new approach that combines KCE with 
DNA-encoded ligand technology to build a generic solution based HTS platform for efficient 
and accurate small molecule ligand selections (primary screening); we call it kinetic capillary 
electrophoresis facilitated DNA-encoded ligand selection (KCE-DEL). Furthermore, we are also 
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developing a kinetic size-exclusion chromatography-mass spectrometry (KSEC-MS) approach 
for label-free solution-based kinetic analysis of target-ligand interactions (secondary screening). 
For our methods to be generic and reliable, the following requirements have to be fulfilled. (i) 
The primary screening methods should be efficient and accurate. (ii) The primary screening 
methods should also be applicable to wide range of samples. (iii) For secondary screening, the 
methods of choice should be compatible with generic label-free detection. (iv) For secondary 
screening, the developed methods should be accurate in assessing the true kinetic parameters. (v) 
For secondary screening, the developed methods should be robust and applicable for various 
samples with different conditions. In the following chapters, we will tackle above-mentioned 
requirements step by step and present KCE-DEL and KSEC-MS as novel kinetic solution-based 
approaches in facilitating small molecule drug discovery. 
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CHAPTER 2. PREDICTION OF PROTEIN–DNA COMPLEX 
MOBILITY IN GEL-FREE CAPILLARY ELECTROPHORESIS 
 
The presented material was published previously and reprinted with permission from “Bao, 
J., Krylova, S. M., Cherney, L. T., Hale, R. L., Belyanskaya, S. L., Chiu, C. H., Arico-Muendel, 
C. C., & Krylov, S. N. (2015). Prediction of Protein–DNA complex mobility in gel-free capillary 
electrophoresis. Analytical Chemistry, 87(4), 2474–2479. doi:10.1021/ac504504c” Copyright 
2015 American Chemical Society. My contribution to the article was: (i) planning all 
experiments, (ii) designing and synthesising all ligands (iii) performing all experiments, (iv) 
preparing figures, (v) writing the manuscript.  
 
2.1 Introduction  
Selection of protein binders from highly diverse combinatorial libraries (complex 
mixtures) of molecules is an efficient and economical alternative to traditional screening for 
discovery of affinity probes and drug leads [31]. The molecules in the most diverse libraries, 
with only ∼1–100 copies of every molecule present in a sample, include either DNA or RNA for 
the purpose of binder identification. The unique property of DNA is that it can be amplified by 
PCR and sequenced to reveal the binder’s identity. RNA, on the other hand, can be easily 
converted into DNA, which can then be amplified and sequenced. The examples of such libraries 
are (i) random DNA (or RNA) libraries used for selection of oligonucleotide aptamers [32, 33], 
(ii) mRNA-display libraries containing chimeras of mRNAs with peptides that they encode and 
used to select protein-binding peptides [34], and (iii) DNA-encoded libraries of small molecules 
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used for selection of small-molecule protein binders [35]. For any specific library, the 
oligonucleotides have identical lengths and are the bulkiest parts of the molecules. They largely 
define the physical properties of the library molecules such as size and electrical charge, so that 
other parts, even when present, can be neglected if these physical properties are of major 
importance. Therefore, for a general consideration of the physical properties of molecules, we 
can assume that the protein binds DNA and we will use this simplification unless the details are 
essential. 
In the binder selection procedure, the library is mixed with the protein target to allow 
library molecules to bind the target. The target-bound molecules are partitioned from the target-
unbound ones. The collected bound molecules are dissociated from the protein and identified by 
sequencing their DNA (or DNA complement of RNA). The partitioning step must be very 
efficient to ensure that the binders are not lost while the nonbinders are removed. Typically, 
partitioning is done by using surface-based approaches: separation on filters that retain the 
protein but let DNA (RNA) through or affinity chromatography with the protein immobilized on 
the stationary phase and retaining the binders [36].  
Surface-based techniques suffer from low partitioning efficiency caused by nonspecific 
binding of the library molecules to the surface of the filter or the stationary phase. The fraction of 
the library that nonspecifically binds to the surface can be as high as 15% [37]. Such a high 
background decreases the efficiency of the selection procedure. It is especially detrimental for 
selection of binders from DNA-encoded libraries of small molecules. Unlike random DNA 
libraries and mRNA display libraries, the libraries of DNA-encoded small molecules cannot be 
propagated because small molecules are not amplifiable. Therefore, enrichment of true binders 
must be achieved within a few rounds of selection, which, in turn, requires high partitioning 
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efficiency of separation methods used in the selection. Failure to successfully select protein 
binders from the three types of libraries considered here can be caused by low partitioning 
efficiency of the surface-based separation methods used [38]. 
Gel-free capillary electrophoresis (CE) is a solution-based separation technique and a 
highly promising alternative to surface-based techniques for partitioning protein–DNA 
complexes from the unbound DNA library. The separation in CE is based on different 
electrophoretic mobilities of DNA and protein–DNA complexes; the protein–DNA complex 
always has a greater friction coefficient (of the drag force) and a lower negative charge density 
than unbound DNA. Moreover, all DNA molecules of the same length have similar mobilities 
and migrate as a single electrophoretic zone. All complexes of the same-length DNA with the 
same protein also have similar mobilities and migrate as a single electrophoretic zone. When a 
bare fused silica capillary is used along with a pH-neutral separation buffer, there is always an 
appreciable electroosmotic flow (EOF) from the positive-electrode end to the negative-electrode 
end of the capillary. The absolute value of EOF mobility is greater than those of DNA and 
protein–DNA complexes while the direction is opposite. As a result, DNA and protein–DNA 
complexes injected at the positive-electrode will move toward the negative-electrode end 
(despite their overall negative charges) with the complexes moving faster (Figure 2.1A). The 
complexes can be collected at the capillary outlet before the unbound DNA reaches the end. The 
greater time window between the complexes and unbound DNA will result in a greater 
partitioning efficiency (Figure 2.1B). The background can originate from unbound DNA moving 
along with the protein–DNA complex [39]. A wide time window between the zones of the 
complex and unbound DNA guarantees very low background, which must be much lower than 
that of surface-based methods [40].  
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Figure 2.1. Conceptual depiction of migration patterns of DNA, protein, and complex. (A) 
The sample that contains DNA, protein, and complex is injected into the capillary at t = 0. 
Under high voltage, all three components start to migrate toward the outlet yet separate from 
each other based on their size to charge ratios. The complete separation is achieved at t = 1. 
(B) The graph illustrates the corresponding migration times of DNA, protein, and complex. 
  
The above advantages of gel-free CE led to its practical use for analytical and preparative 
separation of protein–DNA complexes. Methods of kinetic capillary electrophoresis (KCE) were 
successfully utilized for measuring rate constants of complex formation, kon, and dissociation, 
koff, and equilibrium dissociation constant, Kd [29, 30, 41-43]. KCE methods were also used for 
selection of protein binders from DNA libraries [44]. In particular, DNA aptamers were selected 
for a number of proteins [45]. Uniquely, KCE methods allowed selection of aptamers with 
desirable ranges of koff and Kd values [46]. The library enrichment is typically completed in 1–4 
rounds of partitioning in contrast to 10–20 rounds usually required with surface based methods 
[47]. Such high speed of enrichment is explained by an extremely low level of background of 
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<0.01% [48]. The use of KCE methods was also suggested for selection of protein binders from 
libraries of DNA-encoded small molecules, and some performance parameters have been 
experimentally evaluated for this application [43].  
Selection of protein binders from DNA libraries requires collection of a fraction of the 
intact protein–DNA complex (and/or free DNA that originated from the dissociation of protein–
DNA complex) during electrophoresis. Accurate fraction collection requires the knowledge of 
migration time of protein–DNA complexes. In some instances, adding a great excess of protein 
to the library leads to creation of nonspecific protein–DNA complexes that can be detectable 
[49]. However, this approach does not work when the protein does not have a tendency of 
binding DNA nonspecifically. Blind fraction collection has high odds that either the complex 
will not be collected or a large amount of “background” DNA will be collected along with the 
complex. The latter is an indicator of inefficient partitioning that can be detrimental for selection, 
especially from nonamplifiable libraries of DNA-encoded small molecules. Therefore, it is of 
great importance for KCE-based selection of protein binders to have a method of accurate 
prediction of protein–DNA complex mobility. Here we present such a method for complexes of 
proteins with DNA-encoded small molecules. In this case we use a model of a globular protein 
with a rigid dsDNA attached to the protein in a single point (Figure 2.2).  
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Figure 2.2. Schematic representation of the complex of globular protein and rod-like dsDNA, 
linked through a small molecule, capable of binding the protein. This model mimics the 
complex between a protein and a DNA-encoded small molecule with the dsDNA part. The 
lower part illustrates relative values of velocities of EOF, protein, DNA, and protein–DNA 
complex. 
 
The model is based on a theory of the thin double layer and corresponding expressions used for 
the mobilities of a rod-like short oligonucleotide and a sphere-like globular protein. It uses 
empirical data for mobilities of free DNA and free protein, which can be easily determined 
experimentally. To test the developed mathematical model, we used binding of streptavidin to 
biotin-labeled dsDNA of different lengths. The results show that the model can predict the 
mobility of protein–DNA complex with an error of less than 4% and the travel time of protein–
DNA complex to the detector with error less than 6%. It can thus aid selection of protein binders 
from libraries of DNA-encoded small molecules and advance the use of such libraries in 
identifying drug leads and diagnostic probes. 
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2.2 Materials and Methods 	  
2.2.1 Chemicals and Materials 
Fused-silica capillary was purchased from Polymicro (Phoenix, AZ). All reagents were 
dissolved in 50 mM Tris-HCl, pH 8.0. The 40, 80, and 120 dsDNA were synthesized by PCR, 
and a pETMutS plasmid was used as a template (Addgene plasmid 13245, Cambridge, MA). All 
DNA primers were purchased from IDT DNA Technology Inc. (Coravile, IA). DNA primer 
sequences were 
Forward primer: FAM 5′-CCGACTACCTCCTCCTCTTC-3′ 
Reverse primer 40: Biotin 5′-TCGTAGAAGTCCCCCACCTG-3′ 
Reverse primer 80: Biotin 5′-CAGGGCGCGGGCCA-3′ 
Reverse primer 120: Biotin 5′-TGGTGAAGTCCTTGCTGGTC-3′ 
All PCR products were subjected onto a 2% agarose gel, and the bands that contained dsDNA 
were excised and purified by using a QIAquick Gel Extraction Kit (Toronto, ON, Canada). The 
purified dsDNA were quantified by using fluorescence detection at 520 nm. The FAM-labeled 
forward primer was used as a concentration standard. The streptavidin (Sigma-Aldrich, Oakville, 
ON, Canada) was labeled with a fluorogenic dye, Chromeo 488 (Active Motif, Carlsbad, CA) 
overnight at 4 °C. Bodipy was purchased from Life Technologies Inc. (Burlington, ON, Canada). 
All other regents were purchased from Sigma-Aldrich (Oakville, ON, Canada). All solutions 
were made using deionized water filtered through a 0.22 µm filter (Millipore, Nepan, ON, 
Canada). 
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2.2.2 Instrumentation 
The ABI7300 real time PCR (BioRad, Mississauga, ON, Canada) was used to synthesis 
dsDNA. The Owl D2 Wide-Gel Electrophoresis System (Thermo Scientific, Wilmington, DE) 
was used to purify the PCR products. NanoDrop 3300 fluorospectrometer (Thermo Scientific, 
Wilmington, DE) was used for dsDNA quantification. All CE experiments were carried out with 
MDQ-PACE instrument (Beckman-Coulter, ON, Canada) equipped with a laser-induced 
fluorescence (LIF) detector. LIF signal was recorded at 520 nm (for fluorescein, FAM, and 
bodipy detection) and 605 nm (for chromeo-streptavidin detection) with 4 Hz acquisition rate. 
The inner diameter of the capillary was 75 µm. The total capillary length was 81.2 cm with 71.2 
cm from the injection end to the detection window. 
 
2.2.3 Migration Analysis by CE–LIF 
The 50 mM Tris-HCl, pH 8.0 buffer was used for both incubation and separation. The 
binding mixture was made by incubating 100 nM dsDNA, 1 µM chromeo-labeled streptavidin, 
10 nM fluorescein (internal standard), and 5 µM bodipy (neutral marker), at 20 °C for 30 min. 
The control mixture was the same as binding mixture yet without streptavidin. The capillary was 
flushed prior to each CE run with 0.1 M HCl, 0.1 M NaOH, ddH2O, and buffer. The sample was 
injected into the capillary at 0.5 psi for 10 s. The ends of the capillary were inserted into the inlet 
and outlet reservoirs, and an electric field of 308 V/cm was applied to carry out electrophoresis. 
The temperature of the capillary was maintained at 15 °C. All experiments were performed in 
triplicates. 
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2.3 Results and Discussion 
 
2.3.1 Mathematical Model 
In this work, we concentrate on libraries of DNA-encoded small molecules in which the 
DNA part is dsDNA of ∼120 base pairs in length. This case describes a class of practical 
libraries of DNA encoded small molecules used in the pharmaceutical selection of drug leads 
[50].  
Proteins have been used as tags to cause DNA mobility shift in DNA sequencing [51]. The 
general separation approach dealing with such molecular chimeras is termed End-Labeled Free-
Solution Electrophoresis (ELFSE) of DNA. To aid processing data from ELFSE-of-DNA 
experiments, theoretical models of ELFSE have been developed [52-58]. Such models usually 
employ the blob theory that is applicable to DNA, which is sufficiently long to be considered a 
semiflexible random coil [56, 58]. The polymer can be considered a semiflexible random coil if 
its contour length L is much larger than the Kuhn length bK characterizing the polymer stiffness 
[59, 60]. This assumption is not satisfied for ∼120 base pairs long dsDNA for which LDNA < 41 
nm while bK,DNA > 100 nm. Here and below, “DNA” in the subscript indicates that the 
corresponding parameter describes dsDNA. Thus, the usual ELFSE models, which are based on 
the blob theory, cannot be used in our case. 
Taking into account that LDNA is smaller than bK,DNA, we use a different approach assuming 
that dsDNA (containing ≤120 base pairs) behaves like a rigid rod. The dsDNA diameter, dDNA, 
can be estimated as 2 nm [61,62]. which is larger than the Debye length for the buffer, λD, and 
the dsDNA length LDNA is many times larger than λD. Thus, we can assume that the dsDNA 
mobility, µDNA, is estimated by an expression used in a theory of the thin double layer [52,56]:  
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0 r DNA DNA D DNA D
DNA DNA
0 r
ε ε ζ σ λ σ λ
µ ζ
η η ε ε
⎛ ⎞− −
= ≈ ≈⎜ ⎟
⎝ ⎠
   (2-1) 
Here, ε0 is the vacuum permittivity, εr is the relative permittivity of the buffer, ζDNA is the zeta 
potential of dsDNA, σDNA is the surface density of the electric charge in the diffuse part of the 
double layer around dsDNA (i.e., excluding the Stern layer), and η is the dynamic viscosity of 
the buffer. Equation 2-1 can be rewritten as follows: 
DNA D DNA D DNA
DNA DNA
DNA DNA
,q q
d d
σ λ λ
µ σ
η πη π
−
= = = −     (2-2)  
where qDNA is the charge per unit length of dsDNA. In calculations of qDNA, we should take into 
account the condensation of the counterions on dsDNA [63,67]. The condensation takes place for 
cylindrical objects with the linear density electric charge, q, satisfying relations [63]: 
|q |! qeff , qeff =
e
z i!B
, !B =
e 2
4!"0!rkBT
     (2-3) 
Here, e is the charge of proton, zi is the valence of counterions, λB is the Bjerrum length, kB is the 
Boltzmann constant, and T is the absolute temperature of the buffer. Usually, dsDNA has two 
negative charges per 0.34 nm of its length [56] and λB = 0.7 nm for water solutions at room 
temperature [55, 65]. Thus, equation 2-3 is always satisfied for dsDNA and condensation of 
counterions reduces the density of the DNA charge qDNA (excluding the Stern layer) to the 
effective value, −qeff, determined by the second equation 2-3 [63]. Since we also consider the 
Stern layer as a part of the condensed counterion layer, then |qDNA| will be even less than qeff. In 
this case qDNA can be considered as an adjustable parameter. We should note that the dsDNA 
mobility has negative values since dsDNA is negatively charged. Equation 2-2 for µDNA can be 
also obtained from the balance of electric and hydrodynamic forces, FE,DNA and FH,DNA, acting 
upon dsDNA: 
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E,DNA H,DNA 0F F+ =         (2-4) 
if we assume the following effective values for these forces: 
DNA DNA
E,DNA DNA DNA H,DNA DNA
D
, d LF q L E F uπη
λ
= = −     (2-5) 
Here, E is the electric field strength and uDNA is a relative velocity of dsDNA with respect to the 
buffer. Hereafter we use a coordinate system in which electric and hydrodynamic forces have 
only x-components. 
The average diameter dP of a globular protein with the molecular weight >10 kDa can be 
estimated as 3 nm [68]. Thus, dP is significantly larger than λD. In this case, the protein mobility 
µp can be determined by expression similar to equation 2-1: 
0 r P P D P D
P P
0 r
ε ε ζ σ λ σ λ
µ ζ
η η ε ε
⎛ ⎞− −
= ≈ ≈⎜ ⎟
⎝ ⎠
     (2-6) 
Here, ζP is the zeta potential of the globular protein, and σP is the average surface density of the 
electric charge in the diffuse part of the double layer around the protein (i.e., excluding the Stern 
layer). Equation 2-6 can be also rewritten as follows: 
P D P D P
P P2 2
P P
,Q Q
d d
σ λ λ
µ σ
η πη π
−
= = = −       (2-7) 
where QP is the electric charge of protein (including the Stern layer charge). We should note that 
the protein mobility can have both positive and negative values (for positively and negatively 
charged proteins, respectively). 
Equation 2-7 for µP can also be obtained from the balance of electric and hydrodynamic forces, 
FE,P and FH,P, acting upon the protein molecule: 
E,P H,P 0+ =F F          (2-8) 
if we assume the following effective values for these forces: 
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2
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E,P P H,P P
D
, πη
λ
= = −
dF Q E F u       (2-9) 
Here, uP is the relative velocity of the protein with respect to the buffer. 
The mobility of dsDNA with a globular protein attached to its end can be found from the balance 
of all effective forces acting upon such a complex: 
FE,DNA + FE,P + FH,DNA + FH,P = 0        (2-10) 
Substitution of equations 2-5 and 2-9 into equation 2-10 gives 
( )
2
DNA DNA P
DNA DNA P comp
D D
d L dq L Q E uπη πη
λ λ
⎛ ⎞
+ = +⎜ ⎟
⎝ ⎠
    (2-11) 
Solving this equation with respect to ucomp and taking into account that ucomp = µcompE we obtain 
the complex mobility µcomp: 
DNA DNA P
comp 2
DNA DNA P
D D
q L Q
d L d
µ
πη πη
λ λ
+
=
+
      (2-12) 
Taking into account equations 2-2 and 2-7 for the mobilities of dsDNA and the globular protein, 
we can rewrite the equation 2-12 as follows: 
2
DNA DNA DNA P P
comp 2
DNA DNA P
d L d
d L d
µ µ
µ
+
=
+
      (2-13) 
Using equation 2-13 for the complex mobility, we can readily find the complex travel time to the 
detector, tcomp, 
comp
EOF comp
Lt
v Eµ
=
+
        (2-14) 
Here, L is the distance from the beginning of the capillary to the detector, and vEOF is the velocity 
of EOF in the capillary. 
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It should be noted that the final equation 2-13 for complex mobility does not contain 
charges of dsDNA and protein. We excluded them using equations 2-2 and 2-6 for the mobilities 
of dsDNA and protein. Thus, we do not need to know the charges of dsDNA and protein to 
calculate complex mobility since we can experimentally determine the mobilities of dsDNA and 
protein. In this case, the charges of dsDNA and protein can be back calculated from equations 2-
2 and 2-6 using their experimentally found mobilities and, therefore, can be considered as 
adjustable parameters. 
 
2.3.2 Experimental Validation of Mathematical Model 
To validate our mathematical model expressed by equations 2-13 and 2-14, we needed a 
protein that binds dsDNA at its end and we needed to determine mobilities of free protein and 
free dsDNA as well as the EOF velocity. We chose streptavidin and biotinylated dsDNA as a 
binding pair. Streptavidin can bind to biotin with exceptionally high affinity. Three lengths of 
dsDNA were used (NDNA = 40, 80, and 120 base pairs) to test theory applicability for different 
DNA lengths. All experiments were performed in triplicates. Figure 2.3 shows representative 
electropherograms for the neutral marker (bodipy), free protein, internal standard (fluorescein), 
free biotinylated dsDNA, and protein–dsDNA mixture. The velocity of EOF was measured and 
found to be vEOF = 0.1247 ± 0.0002, 0.1249 ± 0.0002, and 0.1193 ± 0.0017 cm/s for experiments 
with NDNA = 40, 80, and 120 base pairs, respectively. Mobilities of both dsDNA (in the absence 
of the protein) and the protein (in the absence of dsDNA) were found to be negative, which 
means that both dsDNA and protein are negatively charged. As a result the complex turned out 
to be negatively charged and its experimentally measured mobility is negative. Measurements of 
the dsDNA mobility resulted in the following absolute mobility values: |µDNA| = 0.2678 ± 
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0.0005, 0.2747 ± 0.0014, and 0.2784 ± 0.0002 cm2/kV s for NDNA = 40, 80, and 120 base pairs, 
respectively. Measurements of the protein mobility revealed |µp| = 0.0401 ± 0.0006, 0.0403 ± 
0.0012, and 0.0384 ± 0.0006 cm2/kV s for experiments with NDNA = 40, 80, and 120 base pairs, 
respectively. Thus, the absolute value of protein mobility is significantly less than that of 
dsDNA. The mobilities of the complexes were found to be |µcomp| = 0.1643 ± 0.0006, 0.2007 ± 
0.0022, and 0.2195 ± 0.0006 cm2/kV s for NDNA = 40, 80, and 120 base pairs, respectively. Thus, 
a complete set of experimental data required for model validation needs to be obtained.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Migration information on all components. The migration patterns of 40, 80, and 
120 dsDNA are shown in parts A, B, and C, respectively. In each panel, the top two traces 
represent a control experiment with different detection wavelengths. The control contains 100 
nM dsDNA, the neutral marker (NM), and the internal standard (IS). The bottom two traces 
represent binding, which has the same composition as control plus 1 µM chromeo-streptavidin 
protein. The binding complex was highlighted with the red box. All experiments were 
performed in triplicates. 
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In addition to the described experimental values of mobilities and velocities, we needed to 
know the hydrodynamic sizes of the streptavidin (dP) and dsDNA (dDNA and LDNA). We used a 
value of dDNA = 2.6 nm, which includes the hydration shell around dsDNA [69], and a value for 
the streptavidine molecule diameter, dp = 5.3 nm, determined from crystallographic studies [70]. 
The dsDNA length was calculated as LDNA = bDNANDNA, where bDNA = 0.34 nm is the dsDNA 
monomer length [56].  
We used the described parameters in eqs 2-13 and 2-14 to calculate predicated mobilities 
and travel times to the detector for protein–dsDNA complexes at different lengths of dsDNA. 
Figure 2.4 shows absolute values of the experimental and theoretical mobilities of the protein–
DNA complexes. According to the results in Figure 2.4, the developed model can predict the 
mobility of the protein–DNA complex with an error of less than 4% and the travel time of the 
protein–DNA complex to the detector with error less than 6%. It should be noted that different 
models were proposed for the mobility of rigid composite objects formed by a rod and a sphere 
[55, 71]. In these models, only one part (the rod or the sphere) is charged whereas in our case 
both parts (the rod-like dsDNA and the globular protein) can be charged.  
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Figure 2.4. Dependences of the protein-dsDNA complex mobility (top) and travel time to the 
detector (bottom) on the number of base pairs in dsDNA.Mobilities and migration times of 
dsDNA and protein are also shown. Experimental results are shown by lines with open 
markers while theoretical results are shown by lines with solid markers. Theoretical values 
were obtained from equations 2-13 and 2-14. 	  
Extension of these models to our case results in the following equation for the complex mobility 
DNA DNA P P
comp
DNA P
ξ µ ξ µ
µ
ξ ξ
+
=
+
       (2-15) 
Here ξDNA and ξP are the friction coefficients of a rod and a sphere defined by relations [55, 72]: 
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Equation 2-15 differs from equation 2-13 that we obtained and is used to predict the complex 
mobility. In particular, equation 2-15 depends on dDNA only logarithmically (very weakly). 
Calculation based on eqs 2-15 and 2-16 give |µcomp| = 0.1496, 0.1748, and 0.1909 cm2/kV s for 
NDNA = 40, 80, and 120 base pairs, respectively. Comparing these theoretical values of complex 
mobility to ones experimentally determined above we can conclude that equation 2-15 results in 
13% relative error in prediction of complex mobility whereas our equation 2-13 leads to only 4% 
error. 
 
2.4. Conclusions 
To summarize, we developed an approach for accurate estimation of the mobility of 
protein–dsDNA complex. The approach uses an approximation of a globular protein and a rod-
like dsDNA. It will aid in selection and characterization of protein binders from libraries of 
DNA-encoded small molecules by methods of KCE. The general approach developed here can 
be utilized to develop similar models for other types of DNA libraries. In this proof of principle 
study, our model successfully predicted the migration of complex containing pure dsDNA 
ligand. However, in real selections, most DNA-encoded small molecule libraries comprise the 
DEL with both ssDNA and dsDNA regions. Therefore in the next chapter, we will introduce a 
new method for mobility calculations of protein-DNA complexes that contain both ssDNA and 
dsDNA regions.  
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CHAPTER 3. PREDICTING ELECTROPHORETIC MOBILITY 
OF PROTEIN-LIGAND COMPLEXES FOR LIGANDS FROM 
DNA-ENCODED LIBRARES OF SMALL MOLECULES 
 
The presented material was published previously and reprinted with permission from “Bao, 
J., Krylova, S. M., Cherney, L. T., Hale, R. L., Belyanskaya, S. L., Chiu, C. H., Shaginian, A., 
Arico-Muendel, C. C., & Krylov, S. N. (2016). Predicting Electrophoretic mobility of Protein–
Ligand complexes for ligands from DNA-Encoded libraries of small molecules. Analytical 
Chemistry, 88(10), 5498–5506. doi:10.1021/acs.analchem.6b00980” Copyright 2016 American 
Chemical Society. My contribution to the article was: (i) planning all experiments, (ii) designing 
and synthesising all ligands except for two ligands provided by GlaxoSmithKline (iii) 
performing all experiments, (iv) interpreting the results, (v) preparing figures, (vi) writing the 
manuscript.  
 
3.1 Introduction 
In the previous study, we have successfully developed the KCE based ligand screening 
method, which can be potentially used for efficient and accurate primary drug screening. 
However the former model was built to predict protein-DNA complex migration with pure 
dsDNA; in real drug selections, most of the DNA-encoded ligands consists both dsDNA and 
ssDNA regions. Therefore, in this study, we are introducing a more generic model, which is 
applicable in real DEL selection. 
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Finding molecules that can selectively bind therapeutic targets is the initial step in most 
mainstream approaches of modern drug development [73-75]. Selection of protein binders 
(ligands) from DNA-encoded libraries of small molecules (DELSMs) is one such approach [76, 
77]. DELSMs provide a solution for the main dilemma of selection of ligands from highly 
diverse mixtures of molecules. On one hand, the probability of finding ligands increases with 
increasing diversity of the mixture. On the other hand, the increasing diversity decreases the 
number of copies of unique molecules in the mixture, making their identification impossible by 
classical structure-analysis methods. In DELSMs, the structure of every small molecule is 
encoded in its DNA tag and can thus be revealed by amplifying and sequencing the tag. The 
efficiencies of polymerase chain reaction (PCR) and DNA sequencing are so high [78] that 
selecting a few copies of each ligand from a DELSM is sufficient for identification of its 
structures. As a result, DELSMs with diversities of more than 1 billion structures are synthesized 
and used for drug-lead selection [79].  
The concept of DELSM was introduced in 1992 [76], and since then a number of synthetic 
approaches to the generation of DELSMs have been developed (Figure 3.1) [35, 80]. Different 
synthetic approaches lead to different structures of DNA tags. In general, DNA tags are linear 
DNA of two types: pure double-stranded DNA (dsDNA) and ds-ssDNA chimeras composed of 
dsDNA and single-stranded DNA (ssDNA) fragments.  
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Figure 3.1 Schematic representation of assembly routes and corresponding structures of 
various DELSMs. (left to right) encoded self-assembling chemical (ESAC) library, DNA-
templated synthesis (DTS) “end-of-helix” architecture, DTS internal architecture, sequential 
assembly templated, and sequential assembly	  untemplated.	  Building	  blocks	  of	  the	  small-­‐molecule	  head	  and	  DNA	  fragments	  encoding	  them	  are	  shown	  by	  the	  same	  colour. 
 
In chapter 2, we have demonstrated that methods of kinetic capillary electrophoresis (KCE) 
may facilitate highly efficient homogeneous selection of ligands from DELSMs with pure 
dsDNA structures. Here we present a more generic model that can be equally applied to 
DELSMs with more sophisticated structures of DNA tags. The new model considers a globular 
protein attached to the DNA tag at a single point. The thin double layer model is used to find 
mobilities of protein, dsDNA, and ssDNA. Given these mobilities, effective electric and 
hydrodynamic forces acting upon protein, dsDNA, and ssDNA are determined. Then the 
mobility of protein–dsDNA–ssDNA complex is obtained from the equation of balance of all 
forces acting upon the complex. Finally, complex mobility is expressed in terms of 
experimentally measurable mobilities of protein and dsDNA–ssDNA chimera. 
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We derived an expression that links the unknown electrophoretic mobility of the protein–
ligand complex with empirical data for electrophoretic mobilities of the protein and library. To 
test the developed mathematical model, we used binding of streptavidin (SA) to biotin-labeled 
dsDNA or ds-ssDNA with varying lengths of dsDNA and ssDNA regions. The predicted 
electrophoretic mobilities and migration times deviated from the experimentally measured ones 
by less than 11%. We also assessed our model by using two proteins, SA and carbonic anhydrase 
II (CAII), and two ligands with tag structures identical to those in actual GSK libraries. 
Deviation of predicted electrophoretic mobility from the experimental measured value did not 
exceed 5% for CAII and 3% for SA. We conclude that the model is adequate and can aid 
selection of protein binders from DELSMs and advance the use of such libraries in identifying 
drug leads and diagnostic probes. 
 
3.2 Materials and Methods 
 
3.2.1 Chemicals and Materials 
Fused-silica capillary was purchased from Polymicro (Phoenix, AZ). All reagents were 
dissolved in 50 mM Tris-HCl at pH 8.0 (unless otherwise specified); the same buffer was used as 
the CE run buffer. All DNA sequences used for constructing ds-ssDNA chimeras were purchased 
from IDT DNA Technology Inc. (Coralville, IA). The sequences were as follows: alexa80, 5′-
alexa-TGA CTC CCA AAT CGA TGT GTT CCG CAA GAA GCC TGG TAA GCG GAG 
AAA GGT CGT TTT ACT GCC CGG TCT ACC TGA TGG CG-3′; alexa60, 5′-alexa-TCC 
GCA AGA AGC CTG GTA AGC GGA GAA AGG TCG TTT TAC TGC CCG GTC TAC CTG 
ATG GCG-3′; alexa40, 5′-alexa-CGG AGA AAG GTC GTT TTA CTG CCC GGT CTA CCT 
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GAT GGC G-3′; alexa20, 5′-alexa-GCC CGG TCT ACC TGA TGG CG-3′; bioTEG-anti20, 5′-
bioTEG-CGC CAT CAG GTA GAC CGG GC-3′; c1ss10, 5′-AAC GAC CTT T-3′; c2ss10, 5′-
CAG GCT TCT T-3′; c3ss10, 5′-TCG ATT TGG G-3′. Alexa is the fluorophore used to label 
DNA; bioTEG indicates biotin linked to triethyleneglycol; and 80, 60, 40, and 20 indicate the 
number of nucleotides in each DNA sequence. The DNA sequences are annealed together to 
make different ds-ssDNA chimeras, detailed structures of which are shown in Figure 3.2. 
Annealing was achieved by incubating corresponding sequences of DNA at 90 °C for 10 min and 
then gradually cooling them down to the room temperature. Bodipy (4,4-difluoro-4-bora-3a,4a-
diaza-s-indacene) was purchased from Life Technologies Inc. (Burlington, ON, Canada). 
Structural details of dsDNA and chimeric-DNA.  
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Figure 3.2. Structural details of dsDNA and chimeric-DNA.  
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SA and CAII were labeled with a fluorogenic dye, chromeo P503 (Active Motif, Carlsbad, 
CA); the chromeo-labeled proteins will be referred to as chromeo-SA and chromeo-CAII. 
Briefly, 10 µL of protein solution (100 µM in 100 mM sodium bicarbonate, pH 8.3) was mixed 
with 6.6 µL of chromeo solution (1 mM in 100 mM sodium bicarbonate, pH 8.3), and then 
incubated at 4 °C overnight in the dark. 
Biotin and Gly-(l)Leu-4-carboxybenzene sulfonamide (GLCBS-l-leucine) were used as 
small-molecule heads for binding to SA and CAII, respectively. The DNA-tagged small 
molecules will be referred to as biotin ligand and GLCBS-l-leucine ligand. Detailed synthetic 
procedures for these ligands were previously described with a modification of the closing primer 
ligation method [35]. Klenow polymerization was eliminated and the longer oligo strand was 
changed to the top, leaving a 31-nucleotide 3′ overhang to provide a noncompetitive priming site 
for more efficient PCR amplification. All other reagents were purchased from Sigma–Aldrich 
(Oakville, ON, Canada). All solutions were made in deionized water filtered through a 0.22 µm 
filter (Millipore, Nepan, ON, Canada). 
 
3.2.2 Instrumentation and Capillary Electrophoresis Conditions 
All CE experiments were carried out on MDQ-PACE instrument (Sciex, Concord, ON, 
Canada) equipped with a laser-induced fluorescence (LIF) detector. LIF signal was recorded at 
520 nm for fluorescein, alexa, and bodipy detection and at 610 nm for detection of chromeo-SA 
and chromeo-CAII. Signal acquisition rate was 4 Hz. Inner diameter of the capillary was 75 µm. 
Total capillary length was 84.3 cm, with 74.2 cm from the injection end to the detection window. 
The capillary was flushed prior to each CE run with 20% bleach, 0.1 M HCl, 0.1 M NaOH, 
deionized H2O, and run buffer. Sample was injected into the capillary at 0.5 psi for 10 s. The 
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ends of the capillary were inserted into inlet and outlet reservoirs, and an electric field of 297 
V/cm with a positive electrode at the injection end was applied to carry out electrophoresis. 
Temperature of the capillary was maintained at 15 °C. All experiments were performed in 
triplicate. 
 
3.2.3 Migration Study of Protein–Ligand Complexes for Mock Ligands 
For each binding mixture, 100 nM biotinylated DNA (either dsDNA or ds-ssDNA) was 
incubated with 1 µM chromeo-SA, 10 nM fluorescein (internal standard), and 5 µM bodipy 
(neutral marker) at room temperature for 30 min. For the control mixture, 100 nM ds-ssDNA 
was incubated with 10 nM fluorescein (internal standard) and 5 µM bodipy (neutral marker), at 
room temperature for 30 min. 
 
3.2.4 Peak Identification of Biotin Ligand 
The following synthetic intermediates were individually tested: biotin ligand head piece 
(native), biotin ligand head piece (denatured), splint with oligo alexa, and oligo alexa. The 
injected sample in each experiment contained 100 nM analyte with 10 nM fluorescein (internal 
standard). 
 
3.2.5 Migration Studies of Protein–Ligand Complexes for GlaxoSmithKline Ligands 
Two binding systems were tested in this study: SA with biotin ligand and CAII with 
GLCBS-l-leucine ligand. Both ligands contain the same DNA structure, shown in Figure 3.3  a 
combination of two dsDNA (total of 94 bp) and two ssDNA (total of 23 nt) regions. For SA 
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experiments, the binding mixture was made by incubating 1 µM chromeo-SA, 100 nM biotin 
ligand, 10 nM fluorescein (internal standard), and 5 µM bodipy (neutral marker), at 20 °C for 30 
min; control mixture was the same as the binding mixture but without protein. For CAII 
experiments, the binding mixture was made by incubating 5 µM chromeo-CAII, 1 µM GLCBS-l-
leucine ligand, 10 nM fluorescein (internal standard), and 5 µM bodipy (neutral marker) at 20 °C 
for 30 min; control mixture was the same as the binding mixture but without protein. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. Peak identification of biotin-DEL. The schematic structures of components are 
illustrated on the left panel; the corresponding electropherograms are on the right panel. Each 
sample contained 100 nM analyzed component with 10 nM internal standard (IS). All 
experiments were done in triplicates. 	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3.3 Results and Discussion 
 
3.3.1 Mathematical Model 
In this work, we consider mobility of a protein–DNA complex in which the DNA is linear 
and is either pure dsDNA or a combination of dsDNA and ssDNA. The dsDNA regions are 
shorter than 72 base pairs, and the ssDNA regions are shorter than 50 nucleotides. This case 
describes a class of actual DELSMs used by pharmaceutical companies in selection of drug leads 
[50]. We assume that the protein is attached to one end of the dsDNA region as shown in Figure 
3.4. This assumption excludes from consideration the “internal architecture” DELSMs (see 
Figure 3.1). 
Proteins have been earlier suggested as tags in DNA sequencing based on electrophoretic 
mobility shift of DNA; the approach is called end-labeled free-solution electrophoresis (ELFSE) 
of DNA. Although ELFSE-based DNA sequencing has never been advanced beyond proof of 
principle, the development of ELFSE helped to make significant progress in mobility theory for 
protein–DNA complexes [52-58]. Such models typically use the blob theory, which is applicable 
to DNA that is sufficiently long to be considered a semiflexible random coil and has a length 
significantly greater than the diameter of the protein [56, 58]. The polymer can be considered as 
a semiflexible random coil if its contour length L is much greater (one or more orders of 
magnitude) than the Kuhn length bK characterizing the polymer stiffness [59, 60]. This 
assumption is not satisfied for dsDNA of fewer than 72 base pairs, for which LdsDNA < 24 nm 
while bK,dsDNA > 100 nm. Here and below, dsDNA and ssDNA in the subscript indicate that the 
corresponding parameters describe dsDNA or ssDNA. Thus, the complex of a protein linked to 
dsDNA can be considered as a rigid object with a diameter of more than 10 nm (for dsDNA at 
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least 20 base pairs long and protein diameter ∼4 nm). For the contour length of ssDNA of fewer 
than 50 nt, we have LssDNA < 21 nm. Thus, LssDNA is of the same order of magnitude as the 
diameter of the protein–dsDNA complex (>10 nm). In this case, blob theory is not applicable. 
Moreover, ssDNA itself cannot be considered as a semiflexible random coil since its length is 
only three times larger than its Kuhn length, bK,ssDNA ∼6 nm [56]. Thus, for DNA of the lengths 
considered here, the protein–dsDNA complex is a rigid object and ssDNA cannot be treated as 
semiflexible random coil. 
 
 
 
 
 
 
 
Figure 3.4. Schematic representation of one example of a complex between a globular protein 
and a ligand from DELSM. Binding is achieved via protein–small molecule interaction. The 
DNA tag in this example is composed of one dsDNA and one ssDNA region. The lower part 
illustrates relative values of velocities of EOF, protein, ligand, and protein–ligand complex. 
 
 
We will study the electrophoretic mobility of a complex formed by a globular protein 
attached to the end of a stretch of DNA that contains at least one dsDNA and one ssDNA regions 
(see Figure 3.4). This model does not describe the case of DTS internal architecture DELSM 
(see Figure 3.1). We consider globular proteins with a molecular weight of ≥30 kDa. Their 
average diameter can be estimated as dP ≥ 4 nm [68]. Thus, dP is larger than the Debye length for 
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the buffer, λD ∼ 1 nm. In this case, the electrophoretic mobility µp of the protein can be estimated 
by an expression used in thin double layer theory [52, 56]:  
0 r P P D P D
P P
0 r
,ε ε ζ σ λ σ λµ ζ
η η ε ε
− −
= ≈ ≈      (3-1) 
Here ε0 is vacuum permittivity, εr is relative permittivity of the buffer, ζP is ζ potential of the 
globular protein, σP is average surface density of electric charge in the diffuse part of the double 
layer around the protein (i.e., excluding the Stern layer), and η is dynamic viscosity of the buffer. 
Equation 3-1 can be rewritten as follows: 
P D P D P
P P2 2
P P
,Q Q
d d
σ λ λ
µ σ
η πη π
−
= = = −       (3-2) 
where QP is electric charge of the protein (including the Stern layer charge). Note that protein 
mobility can have both positive and negative values (for positively and negatively charged 
proteins, respectively). 
Equation 3-2 for µP can be also obtained from the balance of electric and hydrodynamic forces, 
FE,P and FH,P, acting upon the protein molecule: 
E,P H,P 0+ =F F         (3-3) 
if the following effective values for these forces are assumed: 
2
P
E,P P H,P P
D
, πη
λ
= = −
dF Q E F u       (3-4) 
Here, E is electric field strength, uP is relative velocity of the protein with respect to buffer, and 
µP = uP/E. Hereafter, we use a coordinate system in which both electric and hydrodynamic forces 
have only x-components. We will use equation 3-4 in balance of all forces acting upon the 
complex (see equation 3-14 below) to find the complex mobility. 
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Taking into account that LdsDNA is smaller than bK,dsDNA, we assume that dsDNA (shorter than 72 
bp) behaves like a rigid rod. The dsDNA diameter, ddsDNA, can be estimated as 2 nm [61, 62], 
which is larger than λD, while LdsDNA is many times larger than λD. Thus, we can assume that the 
electrophoretic mobility of dsDNA, µdsDNA, is determined by an expression used in thin double 
layer theory [52, 56]:  
0 r dsDNA dsDNA D dsDNA D
dsDNA dsDNA
0 r
,ε ε ζ σ λ σ λµ ζ
η η ε ε
− −
= ≈ ≈    (3-5) 
Here, ζdsDNA is ζ potential of dsDNA and σdsDNA is surface density of the electric charge in the 
diffuse part of the double layer around dsDNA (i.e., excluding the Stern layer). Equation 3-5 can 
be rewritten as follows: 
dsDNA D dsDNA D dsDNA
dsDNA dsDNA
dsDNA dsDNA
,q q
d d
σ λ λ
µ σ
η πη π
−
= = = −    (3-6) 
where qdsDNA is charge per unit length of dsDNA. In calculations of qdsDNA, we should take into 
account the condensation of counterions on dsDNA [63-67]. The condensation takes place for 
cylindrical objects with linear density electric charge, q, satisfying the following relationship 
[63]:  
2
eff eff B
i B 0 r B
| | , ,
4
λ
λ πε ε
≥ = =
e eq q q
z k T
     (3-7) 
Here e is proton charge, zi is the valence of counterions, λB is Bjerrum length, kB is the 
Boltzmann constant, and T is absolute temperature of the buffer. Usually, dsDNA has two 
negative charges per 0.34 nm of its length [56] and λB = 0.7 nm for water solutions at room 
temperature [55, 65]. Thus, equation 3-7 is always satisfied for dsDNA, and condensation of 
counterions reduces the density of DNA charge qDNA (excluding the Stern layer) to the effective 
value −qeff, determined by the second relationship in equation 3-7 [63]. Since we consider the 
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Stern layer as a part of the condensed counterion layer, |qDNA| will be even less than qeff. In this 
case, qDNA can be considered as an adjustable parameter. We should note that dsDNA mobility 
has negative values since dsDNA is negatively charged. 
Equation 3-6 for µdsDNA can be also obtained from the balance of electric and hydrodynamic 
forces, FE,dsDNA and FH,dsDNA, acting upon dsDNA: 
E,dsDNA H,dsDNA 0F F+ =        (3-8) 
if we assume the following effective values for these forces: 
dsDNA dsDNA
E,dsDNA dsDNA dsDNA H,dsDNA dsDNA
D
, d LF q L E F uπη
λ
= = −
 (3-9) 
Here udsDNA is relative velocity of dsDNA with respect to buffer. We will use equation 3-9 (and 
similar expressions obtained for ssDNA) in the equation of balance of all forces acting upon the 
complex to find the complex mobility. 
Similarly to equation 3-5, we can determine the electrophoretic mobility of ssDNA using an 
expression from thin double layer theory: 
µssDNA =
!0!r"ssDNA
#
!
"$ ssDNA%D
#
, "ssDNA !
"$ ssDNA%D
!0!r
   (3-10) 
Here, ζssDNA is ζ potential of ssDNA and σssDNA is surface density of electric charge in the diffuse 
part of the double layer around ssDNA. Equation 3-10 can be rewritten as follows: 
ssDNA D ssDNA D ssDNA
ssDNA ssDNA
ssDNA ssDNA
,q q
d d
σ λ λ
µ σ
η πη π
−
= = = −     (3-11) 
where dssDNA is ssDNA diameter and qssDNA is charge per unit length of ssDNA. To find qssDNA, 
we also have to take into account condensation of counterions on ssDNA and the Stern layer 
charge [63-67].   
Equation 3-11 can be obtained from the balance of all effective forces acting upon ssDNA: 
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E,ssDNA H,ssDNA 0F F+ =         (3-12) 
where FE,ssDNA and FH,ssDNA are effective electric and hydrodynamic forces acting upon ssDNA. 
They are determined by the following relationships similar to equation 3-9: 
ssDNA dsDNA
E,ssDNA ssDNA ssDNA H,ssDNA ssDNA
D
, d LF q L E F uπη
λ
= = −    (3-13) 
Here ussDNA is relative velocity of ssDNA with respect to buffer. Equation 3-13 will be used in 
equation 3-14. 
The electrophoretic mobility of a globular protein attached to the end of dsDNA, the other end of 
which is linked to ssDNA, can be found from the balance of all effective forces acting upon such 
a complex: 
FE,P + FE,dsDNA + FE,ssDNA + FH,P + FH,dsDNA + FH,ssDNA = 0    (3-14) 
 
Substitution of equation 3-4, equation 3-9, and equation 3-13 into equation 3-14 gives  
QP +qdsDNALdsDNA +qssDNALssDNA( )E =
!"d P
2
!D
+
"#d dsDNALdsDNA
!D
+
"#d ssDNALssDNA
!D
!
"
##
$
%
&&ucomp   (3-15) 
By solving this equation with respect to ucomp and taking into account that ucomp = µcompE, we 
obtain the electrophoretic mobility of the complex, µcomp: 
P dsDNA dsDNA ssDNA ssDNA
comp 2
dsDNA dsDNA ssDNA ssDNAP
D D D
Q q L q L
d L d Ld
µ
πη πηπη
λ λ λ
+ +
=
+ +
    (3-16) 
Taking into account equation 3-2, equation 3-6, and equation 3-11 for electrophoretic mobilities 
of globular protein, dsDNA, and ssDNA, we rewrite equation 3-16 as follows: 
µcomp =
d P
2µP +d dsDNALdsDNAµdsDNA +d ssDNALssDNAµssDNA
d P
2 +d dsDNALdsDNA +d ssDNALssDNA
    (3-17) 
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In the absence of protein, equation 3-17 reduces to the expression for electrophoretic mobility of 
ds-ssDNA chimera, µds-ssDNA: 
µds-ssDNA =
d dsDNALdsDNAµdsDNA +d ssDNALssDNAµssDNA
d dsDNALdsDNA +d ssDNALssDNA
    (3-18) 
Given equation 3-18, we can express the electrophoretic mobility of complex in terms of the 
electrophoretic mobilities of protein and ds-ssDNA chimera: 
( )2P P dsDNA dsDNA ssDNA ssDNA ds-ssDNA
comp 2
P dsDNA dsDNA ssDNA ssDNA
µ µ
µ
+ +
=
+ +
d d L d L
d d L d L
   (3-19) 
By using equation 3-19 for the electrophoretic mobility of complex, we can readily find the 
complex migration time to the detector, tcomp: 
capillary
comp
EOF comp
L
t
v E
=
+ µ
        (3-20) 
Here, Lcapillary is distance from beginning of the capillary to the detector and vEOF is velocity of 
EOF in the capillary. 
Derivation of equation 3-19 for the electrophoretic mobility of complex can be readily 
generalized for the case of ds-ssDNA molecules containing more than one dsDNA region and 
more than one ssDNA section. In this case, equation 3-19 will be still valid if we define LdsDNA as 
total contour length of all dsDNA sections and LssDNA as total contour length of all ssDNA 
sections. 
It is important to emphasize that equation 3-19 does not contain any empirical parameters 
except for the diameter of protein, which can typically be found from independent studies or 
from the literature, and the diameter and length of DNA, which are known. Therefore, no 
“training set” is required for making equation 3-19 eligible, and its general validity can be tested 
with a limited set of experimental data. If experimental systems that are poorly described by this 
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expression are ever found, this would mean that at least one of the following assumptions is not 
fulfilled: 1, the protein is globular, 2, the protein diameter is greater than Debye length (which 
requires that its molecular weight be ≥30 kDa), or 3, the DNA tag is rodlike. However, since the 
utility of the model is to predict an approximate complex mobility for selection of binders, even 
if the prediction has a systematic error, it can still be useful. 
 
3.3.2 Experimental Validation of Mathematical Model 
We used the interaction between SA and biotinylated ds-ssDNA to test our model 
expressed by equation 3-19 and equation 3-20. Biotin played the role of small molecule. The 
interaction between SA and biotin is renowned for its exceptionally high affinity (Kd ≈ 10–14 M). 
We have tested 14 different constructs of ds-ssDNA together with four dsDNA to ensure the 
ruggedness of our model. Detailed structural information for DNA tags used is shown in Figure 
3.2.  
As can be seen in equation 3-19 and equation 3-20, finding the mobility and migration time 
of the protein–DNA complex requires knowledge of the hydrodynamic sizes of protein (dP), 
which is SA in this specific example, and DNA (ddsDNA, dssDNA, LdsDNA, and LssDNA). We used 
values of ddsDNA = 2.6 nm and dssDNA = 1.6 nm, which include the hydration shells around 
dsDNA and ssDNA [69], and a value for SA molecule diameter of dP = 5.3 nm determined from 
crystallographic studies [70]. The dsDNA and ssDNA contour lengths were calculated as LdsDNA 
= bdsDNANdsDNA and LssDNA = bssDNANssDNA, where bdsDNA = 0.34 nm and bssDNA = 0.43 nm, the 
lengths of dsDNA and ssDNA monomers [56]. It is worth recalling that the mathematical model 
was developed with no assumptions on protein or DNA sizes except for the assumption that a 
protein diameter is larger than a Debye length, which is satisfied for proteins larger than 30 kDa. 
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Accordingly, the model is applicable to a wide range of molecular sizes provided that the 
preceding assumption and assumptions of a globular protein and a rodlike DNA are satisfied. In 
general, shorter DNA tags are beneficial, as they would allow small proteins to introduce great 
mobility shifts for the ligands 
In addition to the sizes of protein and DNA, we need to experimentally find electrophoretic 
mobilities and velocities for the protein and DNA tag. Finding these mobilities requires, in turn, 
the knowledge of vEOF. To facilitate finding vEOF, a neutral marker (NM) was added to the 
protein–DNA mixture in each experiment. An internal standard (IS) was added for correcting 
migration time variation between trials. Neither NM nor IS interacted with the ligand or the 
protein. 
SA was labeled with chromeo, a fluorogenic dye that does not change the mobility of 
protein [81]; we also confirmed that the labeling did not significantly affect protein binding to 
biotinylated DNA. The protein could, thus, be detected with laser-induced fluorescence (LIF) at 
610 nm. The biotinylated DNAs were end-labeled with the alexa dye for LIF detection at 520 
nm. Protein–ligand complexes exhibited fluorescence at both wavelengths. Examples of 
migration patterns of protein, ds-ssDNA, and their complex are shown in Figure 3.5.   SA is a 
homotetramer that can bind up to four molecules of biotin, depending on the SA/biotin 
concentration ratio. The peak next to IS at the right corresponds to a complex of one tetrameric 
SA with two molecules of biotin-containing ligand. However, in the present study we focus only 
on the complex with 1:1 stoichiometry.	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Figure 3.5. Migration analysis of complex between chromeo-SA and ds-ssDNA chimera. The 
top two traces represent control experiment with different detection wavelengths. The control 
contains 100 nM ds-ssDNA (60-1), neutral marker (NM), and internal standard (IS). The 
bottom two traces represent binding, which has the same composition as control plus 1 µM 
chromeo-SA. Experimental and theoretical positions of the complex are highlighted with red 
and blue lines, respectively. Traces are offset vertically for clarity. All experiments were 
performed in triplicate, and representative traces are shown. A schematic illustration of 
complex used in these experiments is shown in the top panel. 
 
Electrophoretic mobilities of both free DNA (in the absence of protein) and free protein (in 
the absence of DNA) were found to be negative, which indicated that they were both negatively 
charged. As a result, the complex was also negatively charged and its experimentally measured 
	  	  
	  59 
ds-ssDNA 
name 
Structures Experimental complex 
mobility, mm2/kVs 
Theoretical complex 
mobility, mm2/kVs 
Difference between theoretical 
and experimental complex 
mobility 
20ds  13.39 ± 0.36 12.63 ± 0.39 6% 
40ds  16.44 ± 0.08 16.70 ± 0.01 2% 
80ds  20.07 ± 0.27 20.80 ± 0.13 4% 
120ds  21.95 ± 0.08 22.81 ± 0.01 4% 
40-0  15.15 ± 0.16 14.03 ± 0.70 7% 
60-0  16.74 ± 0.08 17.48 ± 0.12 4% 
80-0  17.76 ± 0.06 18.59 ± 0.07 5% 
40-1  15.82 ± 0.02 16.37 ± 0.05 3% 
60-1  17.05 ± 0.09 18.38 ± 0.11 8% 
60-2  16.87 ± 0.09 18.42 ± 0.04 9% 
80-1  17.64 ± 0.11 19.28 ± 0.07 9% 
80-2  17.73 ± 0.04 19.30 ± 0.05 9% 
80-3  17.63 ± 0.12 19.29 ± 0.07 9% 
60-1-2  16.97 ± 0.03 18.66 ± 0.09 10% 
80-1-2  17.75 ± 0.03 19.35 ± 0.11 9% 
80-2-3  17.65 ± 0.07 19.36 ± 0.08 10% 
80-1-3  17.70 ± 0.05 19.49 ± 0.06 10% 
80-1-2-3  17.61 ± 0.14 19.50 ± 0.03 11% 
 
Precisions of experimental complex mobility and theoretical complex mobility are presented as one 
standard deviation of results from the mean value based on three experiments. 
electrophoretic mobility was negative. The absolute value of protein’s electrophoretic mobility 
was found to be significantly less than that of dsDNA. Using the current model, we calculated 
electrophoretic mobilities (Table 3.1) and migration times (Table 3.2) of complexes for all DNA 
tags. The presence of two markers was essential to ensure the precision of measured migration 
times and calculated mobilities. In our case, RSD was 1% for both mobility and migration times.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.1. Electrophoretic mobilities of complexes between SA and ds-ssDNA chimeras of 
different structures. 
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Table 3.2. Migration times of complexes of streptavidin with ds-ssDNA chimeras of different 
structures. 
 
Electrophoretic mobility of complex increased with the overall contour length, which is 
reasonable, as both DNA and protein are negatively charged; also, as the major contributor to the 
charge, DNA has the major influence on complex mobility. The dsDNA, however, has higher 
electrophoretic mobility than ds-ssDNA with similar contour lengths, which is also anticipated as 
dsDNA has a more rigid rod like shape and hence experiences less friction. On the other hand, 
ds-ssDNA has patches of more flexible ssDNA, which can form random-coil-like structure and 
hence experiences greater friction. This is the likely explanation of systematic overestimation for 
theoretical complex mobility with ds-ssDNA (Table 3.1) as the model was based on the 
assumption of DNA with rigid rod shape; thus, the presence of ssDNA patches introduces 
flexibility and decreases experimental mobility. By comparing the predicted and experimental 
 
 
ds-ssDNA 
name Structures 
Experimental 
complex travel 
time, s 
Theoretical 
complex travel 
time, s 
Difference between theoretical and 
experimental complex travel time 
20ds  999.8 ± 3.7 970.6 ± 6.1 6% 
40ds  961.0 ± 0.4 971.6 ± 2.2 2% 
80ds  1128.7 ± 10.1 1170.3 ± 3.6 4% 
120ds  1377.7 ± 42.9 1453.1 ± 52.3 4% 
40-0  1100.6 ± 18.4 1049.7 ± 41.0 7% 
60-0  1176.3 ± 33.9 1218.2 ± 32.6 4% 
80-0  1305.9 ± 15.9 1364.7 ± 17.9 5% 
40-1  1169.3 ± 7.1 1200.1 ± 3.7 3% 
60-1  1291.2 ± 3.7 1386.4 ± 7.0 8% 
60-2  1283.0 ± 1.3 1394.5 ± 1.6 9% 
80-1  1323.2 ± 1.6 1448.6 ± 7.1 9% 
80-2  1332.3 ± 3.9 1453.8 ± 4.5 9% 
80-3  1340.3 ± 12.4 1471.2 ± 7.6 9% 
60-1-2  1276.5 ± 1.6 1397.5 ± 9.2 10% 
80-1-2  1324.1 ± 2.2 1446.6 ± 10.0 9% 
80-2-3  1336.8 ± 1.9 1470.4 ± 3.4 10% 
80-1-3  1314.1 ± 5.6 1450.6 ± 14.1 10% 
80-1-2-3  1315.2 ± 3.7 1460.4 ± 8.2 11% 
Precisions of experimental complex travel time and theoretical complex travel time are represented by 
one standard deviation of results from the mean of three repeated experiments. 
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values of complex mobility and migration time, we found the accuracy of prediction. For all 
tested DNA tags, deviation of predicted from experimental values did not exceed 11%. The same 
data have also been tested by using the previously developed model, where DNA is considered 
as a rigid rod shape with constant diameter. The old model resulted in approximately doubled 
errors for ds-ssDNA.  
Finally, we tested two ligands, biotin and GLCBS-l-leucine, which were synthesized with 
DNA tags identical to those used in DELSMs by GlaxoSmithKline. Both ligands had the same 
DNA structure: a combination of two dsDNA (total of 94 bp) and two ssDNA (total of 23 nt) 
regions. DNA tags were labeled with alexa to facilitate LIF detection at 520 nm. SA and CAII 
were both labeled with chromeo for their LIF detection at 610 nm. Protein–ligand complexes, 
thus, contained both fluorophores and could be detected at both 520 and 610 nm. 
When sampled in CE without proteins, the unbound ligands revealed several peaks, 
suggesting that, in addition to the ligands, the samples contained impurities. The impurities were 
identified as the starting material and the intermediates from each step of synthesis used for 
manufacturing of DELSMs (Figure 3.3). The full-length ligand contains the most negative 
charge and bears the highest electrophoretic mobility. Accordingly, it was identified as the 
rightmost peak in the electropherogram. In this study, we focused on migration patterns of full-
length ligand and the corresponding protein–ligand complex. 
Electropherograms for protein–ligand binding experiments are shown in Figure 3.6. In 
each panel, the top two traces are the no-protein control and the bottom two traces correspond to 
sampling the protein–ligand mixture. SA is built of four subunits and can bind up to four biotin 
molecules. Accordingly, complexes with different binding stoichiometries are seen in panel A. In 
this study, we considered only 1:1 binding; the corresponding complex is indicated by the red 
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line in panel A. By using our mathematical model, we found electrophoretic mobilities of 
protein–ligand complexes of 21.97 ± 0.09 mm2(kV·s)−1 for biotin ligand and 23.35 ± 0.04 
mm2(kV·s)−1 for GLCBS-l-leucine ligand. Deviations between experimentally and theoretically 
determined complex mobilities were found to be 3% for biotin ligand and 5% for GLCBS-l-
leucine ligand. Such accurate prediction will guarantee accurate collection of protein–ligand 
fraction in selection experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Migration study for protein–ligand complex between (A) 1 µM chromeo-SA and 
100 nM biotin ligand and (B) 5 µM chromeo-CAII and 1 µM GLCBS-l-leucine ligand. In 
each panel, the top two traces represent the no-protein control, which contained 100 nM 
ligand, neutral marker (NM), and internal standard (IS). The bottom two traces correspond to 
the protein–ligand binding experiment, which had the same composition as the control plus 1 
µM protein. Experimental and theoretical positions of the complexes are highlighted with red 
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and blue lines, respectively. Traces are offset vertically for clarity. All experiments were 
performed in triplicate, and representative traces are shown. 
 
3.4 Conclusions 
In conclusion, we have developed a versatile approach for accurate prediction of 
electrophoretic mobility and migration time of protein–ligand complexes for selection of protein 
binders from DELSMs. We consider a globular protein attached to a DNA tag at a single point 
and use the thin double layer model to find mobilities of protein, dsDNA, and ssDNA. We then 
determine effective electric and hydrodynamic forces acting upon protein, dsDNA, and ssDNA 
and express the complex mobility in terms of experimentally measurable mobilities of protein 
and DNA-tagged ligand. The model for complex mobility was tested through studying the 
mobilities of protein–ligand complexes for ligands with varying structures of DNA tags: 4 
dsDNAs and 14 ds-ssDNAs. It was also validated by use of two small molecules with DNA tags 
identical to those used by GlaxoSmithKline in their DELSMs. The accuracy and ruggedness of 
our model were confirmed by comparing predicted complex mobility and migration time with 
experimentally measured values. The model is feasible for analyzing DELSMs with various 
lengths and composition of DNA tags. In addition, the model is generic and expected to be 
applicable to all proteins with near-globular shapes and molecular weights of 30 kDa or more 
and any DELSMs with a rodlike DNA part and a ligand attached to the end of DNA. We foresee 
that this approach will help to advance kinetic capillary electrophoresis methods to their practical 
use in selection of drug leads from DELSMs.  
By now we have successfully developed the primary screening method that is generic and 
applicable for commercial samples. Therefore, the next logical step would be developing a label-
free solution-based method for kinetic analysis of target-ligand interaction. In the former study, 
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we have built KCE-MS, which involves off-line coupling between solution based KCE methods 
and label-free mass spectrometry detection. However as we previously revealed, there was an 
issue of buffer incompatibility. Hence, we took a step back and started looking for the 
physiological conditions that are compatible for target-ligand interactions as well as generic 
label-free mass spectrometry detections. 
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CHAPTER 4. VOLATILE KINETIC CAPILLARY 
ELECTROPHORESIS FOR STUDIES OF PROTEIN-SMALL 
MOLECULE INTERACTIONS 
 
The presented material was published previously and reprinted with permission from “Bao, 
J., & Krylov, S. N. (2012). Volatile kinetic capillary electrophoresis for studies of Protein–Small 
molecule interactions. Analytical Chemistry, 84(16), 6944–6947. doi:10.1021/ac301829t” 
Copyright 2012 American Chemical Society. My contribution to the article was: (i) planning all 
experiments, (ii) performing all experiments, (iii) interpreting the results, (iv) preparing figures, 
(v) writing the manuscript.  
 
4.1 Introduction 
The previous chapters introduced a novel KCE-DEL based approach for primary ligand 
screening, which focuses on selecting target binders from the large populated combinatorial 
library. Subsequently, the selected ligands should be subjected to the secondary screening, in 
which the kinetic parameters are determined for each target-ligand interactions. Evaluations of 
the true kinetic parameters require a label-free analysis with high detection power. Mass 
spectrometry (MS) is a powerful and generic method for label-free small molecule detection. 
This, however, leads to a standard issue of buffer incompatibility with MS-based approaches. 
The standard MS analyses utilize the volatile buffer systems, which are not physiological to 
support interactions between protein and a small molecule. In this study, we are developing a 
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panel of buffer systems that are: (i) volatile and compatible for MS analysis; (ii) physiological 
thus suitable for protein-small molecule interactions.  
Protein–small molecule affinity interactions play an important role in regulatory biological 
processes [16, 82, 83]. Furthermore, the action of most prospective small-molecule drugs is 
based on drugs’ ability to form affinity complexes with their therapeutic targets, which are 
typically proteins [10, 84]. The formation and dissociation of an affinity complex, T-L, between 
protein target, T, and small molecule ligand, L, are characterized by rate constants kon and koff of 
the forward and reverse processes, respectively: 
on
off
T L T-L
k
k
⎯⎯⎯→+ ←⎯⎯
        (4-1) 
and the stability of the complex is described in terms of the equilibrium dissociation constant Kd 
= koff/kon. Since the three constants, kon, koff, and Kd, are interconnected, determining any pair of 
constants will define the third. 
Kinetic affinity methods can measure kon, koff, and Kd for protein–small molecule binding 
and are, thus, essential for understanding the dynamics of biological processes and developing 
protein-binding small-molecule drugs [85]. Such methods fall into two major categories: 
heterogeneous and homogeneous [86]. Heterogeneous methods require the immobilization of a 
small molecule on the surface of a sensor for sensitive detection [87, 88]. The immobilization of 
a small molecule is usually difficult without affecting its ability to bind the protein [89]. 
Homogeneous methods do not require the immobilization of any of the binding partners and are, 
in general, preferred over heterogeneous methods in protein–small molecule studies [90]. 
However, homogeneous methods often require labeling of a small molecule, which reduces 
advantages over heterogeneous methods. 
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Kinetic capillary electrophoresis (KCE) is a toolset of homogeneous kinetic affinity 
methods with a potential application to protein–small molecule studies [30, 43, 91, 92]. 
Conceptually, the protein and small molecule are allowed to interact; then, the protein–small 
molecule complex is separated from the small molecule by capillary electrophoresis, and the 
small molecule is detected at the end of the capillary (the small molecule is chosen for detection 
as it experiences a much greater mobility shift than the protein within the affinity complex). The 
values of kon, koff, and Kd are then determined from the temporal propagation pattern (signal 
versus migration time) of the small molecule. Most KCE applications have been developed with 
fluorescence detection to allow high sensitivity and selectivity [28]. Since the small molecule is 
detected in KCE of protein–small molecule interactions, it should be labeled for fluorescence 
detection. Fluorescent labeling of small molecules is impractical in most cases. 
As an alternative to KCE with fluorescence detection, we have recently suggested KCE 
with mass-spectrometry (MS) detection which can facilitate label-free analysis of protein–small 
molecule binding [29]. A similar approach has also been implemented by Sun and coauthors 
[93]. Our experiments revealed a serious obstacle in the way of making KCE-MS a widely used 
practical tool. Following the “tradition” of affinity methods, KCE has been always run in near-
physiological buffers, such as Tris-acetate and Tris-HCl, when protein–ligand interactions were 
studied. These buffers are not suitable for MS as they suppress ionization and, thus, lead to a 
poor limit of detection (LOD). As an illustration, we compared the LOD for electrospray 
ionization MS of alprenolol dissolved in a nonvolatile Tris-acetate and volatile ammonium 
acetate and found it to be approximately 30 nM and 300 pM, respectively. It is clear that Tris-
acetate cannot be used in KCE-MS of highly stable complexes with low nM affinity as such 
studies need to be conducted at small molecule concentrations below the LOD. In addition, Tris-
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acetate leads to solid deposition at the ionization source, which requires its impractically frequent 
cleaning. We have, thus, been developing approaches to resolve the problem of buffer mismatch 
in KCE-MS. 
While investigating relatively sophisticated modifications to MS, we asked ourselves a 
very simple question: Can volatile buffers that are suitable for MS be used for KCE involving 
proteins? On the one hand, we could not find in the literature references to the use of volatile 
buffers in affinity studies involving proteins. On the other hand, we could not find any reference 
to the incompatibility of protein–ligand interactions with “non-toxic” volatile buffers. We, thus, 
set a goal to test a few volatile buffers in KCE analysis of a few protein–ligand pairs. We chose 
three nontoxic volatile buffers that can be used at neutral pH values: ammonium acetate, 
ammonium bicarbonate, and ammonium formate. Tris-acetate was used as a near-physiological 
buffer control. The three protein–ligand pairs investigated were single-stranded DNA binding 
(SSB) protein with single-stranded DNA (ssDNA), α1-acid glycoprotein (AGP) protein with 
bodipy, and MutS protein with its DNA aptamer. Both DNA molecules were fluorescently 
labeled for detection; bodipy is a fluorescent dye that requires no labeling. 
A KCE method termed nonequilibrium capillary electrophoresis of equilibrium mixtures 
(NECEEM) [94] was used in this work because it allowed us to separately study the influence of 
buffers on protein–ligand complex stability and on separation of unbound ligand from protein–
ligand complex. In NECEEM, an equilibrium mixture of the interactants is first prepared in an 
incubation buffer; a small volume of mixture is sampled for electrophoresis, and the protein–
ligand complex is separated from the unbound ligand in a run buffer. The values of Kd and koff 
can be determined from peak areas in an electropherogram. Equilibrium is established in the 
incubation buffer and, thus, Kd corresponds to the incubation buffer conditions. Complex 
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dissociation, in contrast, occurs in the run buffer; thus, koff is measured under the conditions of 
the separation buffer. The two buffers may be different or the same. 
 
4.2 Materials and Methods 
 
4.2.1 Chemicals and Materials 
Human AGP protein, fluorescein, and all buffer components were obtained from Sigma-
Aldrich (Oakville, ON, Canada). Fluorescently labeled ssDNA oligonucleotides 5′-CCC TAT 
AGT GAG TCG TAT TA-3′ and MutS aptamer 5′-CTT CTG CCC GCC TCC TTC CTG GTA 
AAG TCA TTA ATA GGT GTG GGG TGC CGG GCA TTT CGG AGA CGA GAT AGG 
CGG ACA CT-3′ were purchased from IDT DNA Technology Inc. (Coravile, IA, USA). SSB 
protein from Escherichia coli was ordered from Epicentre Biotechnologies (Madison, WI, USA). 
The UltraTrol dynamic coating was purchased from Target Discovery, Inc. (Palo Alto, CA, 
USA). MutS protein was purchased from GenScript (Piscataway, NJ, USA). Bodipy was 
purchased from Invitrogen (Grand Island, NY, USA). The fused-silica capillaries were purchased 
from Polymicro (Phoenix, AZ, USA). All solutions were made using deionized water filtered 
through a 0.22 µm filter (Millipore, Nepan, ON, Canada). 
 
4.2.2 Instrumentation  
All CE experiments were carried out with an MDQ-PACE instrument (Beckman-Coulter, 
ON, Canada) equipped with a laser induced fluorescent (LIF) detector. All data were recorded 
with a 4 Hz acquisition rate. The inner and outer diameters of the capillary were 50 and 360 µm, 
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respectively. The total capillary length was 38.5 cm with 28.5 cm from the injection end to the 
detection window. 
 
4.2.3 Kinetic Capillary Electrophoresis (KCE) 
 NECEEM was used as the model KCE method. Uncoated fused-silica capillaries were 
used in SSB-ssDNA and AGP-bodipy experiments. The UltraTrol coated capillaries were used in 
MutS–aptamer experiments. Electrophoresis was run in a 30 kV negative polarity for the coated 
capillary and 30 kV positive polarity for the uncoated capillary. The nonvolatile buffer was 25 
mM Tris-acetate, pH 7.2. There are three volatile buffers: 30 mM ammonium acetate, pH 7.2, 30 
mM ammonium bicarbonate, pH 7.8, and 30 mM ammonium formate, pH 7.2. The pre-
equilibrated protein–DNA binding mixtures were prepared by mixing 100 nM protein with 100 
nM DNA and 100 nM fluorescein as internal standard. The AGP-bodipy mixture was made from 
20 µM AGP, 20 µM bodipy with 1 µM fluorescein internal standard. Each control sample 
contains only ligand (DNA or bodipy) with internal standard. The samples were injected into 
capillary by a pressure of 0.5 psi for 10 s. Electrophoresis was carried out with a capillary 
coolant temperature set at 15 °C. All experiments were performed in triplicates. 
 
4.3 Results and Discussion 
First, we studied the influence of volatile buffers on complex stabilities. The interacting 
pairs were incubated in volatile buffers and NECEEM was run in Tris-acetate buffer for all 
volatile incubation buffers. We found that NECEEM electropherograms for volatile incubation 
buffers were similar to the electropherograms for Tris-acetate incubation buffer. The data for the 
MutS–aptamer, SSB-ssDNA, and AGP-bodipy binder interactions are shown in Figure 4.1, 
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Figure 4.2, and Figure 4.3 respectively. These results suggested that volatile buffers did not 
significantly change complex stabilities of the three studied protein–ligand pairs.  
 
 
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  
 
 
 
 
 	  	  
 
 
 
Figure 4.1. NECEEM electropherograms of MutS-aptamer binding analysis under various 
incubation conditions. 25 mM tris-acetate pH 7.2 (A), 30 mM ammonium acetate pH 7.2 (B), 
30 mM ammonium bicarbonate pH 7.8 (C) and 30 mM ammonium formate pH 7.2 (D). The 
non-volatile 25 mM tris-acetate pH 7.2 was used as separation buffer. Blue and red traces 
represent the control and binding respectively. The numbers 1, 2 and 3 indicate the signal of 
free aptamer, internal standard and MutS-aptamer binding complex, respectively. 	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Figure 4.2. NECEEM electropherograms of SSB-ssDNA binding analysis under various 
incubation conditions. 25 mM tris-acetate pH 7.2 (A), 30 mM ammonium acetate pH 7.2 (B), 
30 mM ammonium bicarbonate pH 7.8 (C) and 30 mM ammonium formate pH 7.2 (D). The 
non-volatile 25 mM tris-acetate pH 7.2 was used as separation buffer. Blue and red traces 
represent the control and binding respectively. The number 1, 2 and 3 indicate the signal of 
free ssDNA, internal standard and SSB-ssDNA binding complex correspondingly.  
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Figure 4.3. NECEEM electropherograms of AGP-bodipy binding analysis under various 
incubation conditions. 25 mM tris-acetate pH 7.2 (A), 30 mM ammonium acetate pH 7.2 (B), 
30 mM ammonium bicarbonate pH 7.8 (C) and 30 mM ammonium formate pH 7.2 (D). The 
non-volatile 25 mM tris-acetate pH 7.2 was used as separation buffer. Blue and red traces 
represent the control and binding respectively. The number 1, 2 and 3 indicate the signal of 
free bodipy, internal standard and AGP-bodipy binding complex correspondingly.  
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We then examined how the volatile buffers affected separation of unbound ligands from 
protein–ligand complexes. In these experiments, the run buffers were identical to the incubation 
buffers. We found that free ligands could be separated from protein–ligand complexes in all 
volatile buffers tested. The electropherograms for the MutS–aptamer, SSB-ssDNA, and AGP-
bodipy binder interactions are shown in Figure 4.4, Figure 4.5, and Figure 4.6 respectively. 
Separation was the worst in ammonium acetate; it was the best in ammonium bicarbonate (better 
than in Tris-acetate). Moreover, peak shapes of the DNA aptamer in ammonium bicarbonate and 
ammonium formate differed from classical Gaussian (Figure 4.4, panels C and D). It is known 
that DNA aptamer can fold into various secondary structures under different conditions, such as 
buffer composition, pH, and temperature [95]. Peak shape irregularity is likely caused by the 
formation of multiple secondary structures of the aptamer in these two buffers. We also found 
that different buffers could lead to different binding stoichiometries of the affinity complexes 
(Figure 4.2 and Figure 4.5). SSB protein is a homotetramer, which can bind to more than one 
ssDNA molecule [96]. Two peaks corresponding to the SSB–DNA complex are seen in the 
electropherograms, and the ratio between the peaks changes from buffer to buffer. The peak with 
the shortest migration time most likely corresponds to the complex of SSB with a single DNA 
molecule. The slower migrating complex is likely SSB with two ssDNA molecules. 
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Figure 4.4. NECEEM electropherograms of MutS-aptamer binding analysis by volatile 
incubation and separation buffers. 25 mM tris-acetate pH7.2 (A), 30 mM ammonium acetate 
pH 7.2 (B), 30 mM ammonium bicarbonate pH 7.8 (C) and 30 mM ammonium formate pH 
7.2 (D). Blue and red traces represent the control and binding respectively. The number 1, 2 
and 3 indicate the signal of free aptamer, internal standard and MutS-aptamer binding 
complex correspondingly.  
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Figure 4.5. NECEEM electropherograms of SSB-ssDNA binding analysis by various incubation 
and separation buffers. 25 mM tris-acetate pH7.2 (A), 30 mM ammonium acetate pH 7.2 (B), 30 
mM ammonium bicarbonate pH 7.8 (C) and 30 mM ammonium formate pH 7.2 (D). Blue and 
red traces represent the control and binding respectively. The number 1, 2 and 3 indicate the 
signal of free ssDNA, internal standard and SSB-ssDNA binding complex correspondingly.  
 	  	  	  	  
 
 
 
 
 
 
 	  
	  	  
	  77 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
 	  
 
Figure 4.6. NECEEM electropherograms of AGP-bodipy binding analysis by various incubation 
and separation buffers. 25 mM tris-acetate pH7.2 (A), 30 mM ammonium acetate pH 7.2 (B), 30 
mM ammonium bicarbonate pH 7.8 (C) and 30 mM ammonium formate pH 7.2 (D). Blue and 
red traces represent the control and binding respectively. The number 1, 2 and 3 indicate the 
signal of free bodipy, internal standard and AGP-bodipy binding complex correspondingly.  
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Finally, we have determined Kd values for all three interacting pairs in the four buffers 
studied (Table 4.1). While Kd was found to depend on the buffer (which was expected), most 
values were of the same order of magnitude. The most noticeable effect was that of the 
ammonium format of SSB–DNA complex: complex stability improved to the level at which Kd 
was too small to determine its value accurately. The quantitative results unambiguously suggest 
that volatile buffers did not drastically change complex stability of the three studied protein–
ligand complexes. 
 
 
Table 4.1. Equilibrium dissociation constants (Kd) for 3 pairs of non-covalent protein-ligand 
complexes measured by NECEEM in 3 different incubation/run buffers. 
 
 
 
 
Buffer Kd (nM) 
MutS-aptamer 
Kd (µM) 
AGP-bodipy 
Kd (nM) 
SSB-DNA 
Tris-acetate (control) 47 ± 7 5.8 ± 0.8 1.5 ± 0.3 
Ammonium-acetate 30 ± 3 12.4 ± 0.5 0.5 ± 0.3 
Ammonium-bicarbonate 43 ± 8 17.9 ± 3.3 7.6 ± 6.5 
Ammonium-formate 39 ± 9 3.3 ± 2.5 < 0.5 
A “±” indicates the standard deviation of measurements in triplicates 
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4.4. Conclusions 
The goal of this study was to test if volatile buffers could be used for KCE of protein–
ligand interactions. This test required that we answered two questions: (1) whether or not volatile 
buffers significantly affect reversible protein–ligand binding and (2) whether or not volatile 
buffers can facilitate efficient separation of the protein–ligand complexes from the unbound 
ligands. These questions could be answered with fluorescently labeled ligands and simple 
fluorescence detection without relatively sophisticated KCE-MS schemes. Our study strongly 
suggests that the bias against the use of volatile buffers in studies of protein–ligand interactions 
is not justified. Specifically, volatile buffers can be used in KCE and will, therefore, facilitate 
simple coupling of KCE with MS. The tandem of volatile KCE with MS constitutes a 
homogeneous label-free method that promises to significantly simplify kinetic studies of 
protein–small molecule interactions.  
Up until now, we have developed a panel of volatile buffer conditions that are compatible 
with biomolecule interaction. These buffer systems can facilitate KCE-MS based label-free 
solution-based kinetic analysis. However, as previously discussed in Chapter 1, the KCE based 
approaches are not the best options for protein-small molecule interactions, since neither protein 
nor small molecule is highly charged. Therefore, the separation condition has to be tailored for 
each pair of protein-small molecule interaction. This, however, is contradictory to the goal of 
secondary ligand screening, in which all potential ligands should be evaluated under the same 
condition. Therefore, KCE based methods are not ideal for secondary ligand screening. Size 
exclusion chromatography (SEC) or gel-filtration chromatography separate particles solely based 
on differences in size. Theoretically speaking, SEC is the method of choice for generic solution-
based separation between a protein and small molecule. However, SEC has never been 
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demonstrated for analyzing interactions during separation. Therefore, in the next Chapter, we 
will introduce a novel label-free solution-based kinetic method for protein-small molecule 
interactions analysis. We call it kinetic size-exclusion chromatography mass spectrometry, 
KSEC-MS. 
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CHAPTER 5. KINETIC SIZE-EXCLUSION 
CHROMATOGRAPHY WITH MASS SPECTROMETRY 
DETECTION: AN APPROACH FOR SOLUTION-BASED 
LABEL-FREE KINETIC ANALYSIS OF PROTEIN–SMALL 
MOLECULE INTERACTIONS 
 
The presented material was published previously and reprinted with permission from “Bao, 
J., Krylova, S. M., Cherney, L. T., LeBlanc, J. C. Y., Pribil, P., Johnson, P. E., Wilson, D. K., & 
Krylov, S. N. (2014). Kinetic size-exclusion chromatography with mass Spectrometry detection: 
An approach for solution-based label-free kinetic analysis of Protein–Small molecule 
interactions. Analytical Chemistry, 86(20), 10016–10020. doi:10.1021/ac503391c” Copyright 
2014 American Chemical Society. My contribution to the article was: (i) planning all 
experiments, (ii) performing all experiments, (iii) preparing figures, (iv) writing the manuscript.  
 
5.1 Introduction 
In previous studies, we have developed KCE-DEL based primary ligand screening method 
that focuses on the preliminary selection of all target-binding molecules from the highly 
populated combinatorial library. Besides, we have also developed a panel of volatile buffer 
systems that are physiological to support interaction between the protein target and small 
molecule. In this study, we are going to introduce a novel label-free solution based kinetic 
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method for secondary ligand screening, in which the true kinetic parameters of protein-small 
molecule interactions will be evaluated.  
Reversible binding between small molecules and proteins plays an important role in the 
regulation of various cellular processes [16]. Additionally, such interactions are important in 
modern drug discovery as small molecule drugs are designed to alter protein functions upon 
binding [10, 97, 98]. Understanding the dynamics of both cellular regulation by small molecules 
and the action of small molecule drugs requires knowledge of the kinetics of formation and 
dissociation of protein–small molecule complexes [85, 99, 100]. Thus, it is important to 
determine the rate constants, kon and koff, of the following reaction: 
on
off
P SM P-SM
k
k
⎯⎯⎯→+ ←⎯⎯        (5-1) 
where P is a protein, SM is a small molecule, and P–SM is a protein–small molecule complex. 
Complex stability is typically characterized by an equilibrium dissociation constant Kd = koff/kon 
(smaller Kd values correspond to more stable complexes), and determining any two of the three 
constants will define the third one. 
All current methods used for practical measurements of kon and koff in expression 5-1 are 
either surface-based or label-based. Surface-based methods, such as surface plasmon resonance 
(SPR) [101, 102] and biolayer interferometry [22, 103], require the immobilization of either P or 
SM on the surface of a sensor. Label-based methods, such as stopped flow spectroscopy [104, 
105], require the modification of either P or SM with a spectroscopically detectable label, 
typically a fluorophore. Moreover, it is preferable that SM, rather than P, is immobilized or 
labeled in order to maximize the sensitivity of detection [106, 107]. However, modifications of 
SM are difficult to achieve without drastically affecting its ability to bind P. Therefore, a 
solution-based label-free approach would be ideal for simple and accurate measurements of kon 
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and koff. Here, we propose such an approach, termed kinetic size-exclusion chromatography with 
mass spectrometry detection (KSEC-MS). Size-exclusion chromatography (SEC) allows generic 
separation of SM from P–SM without the immobilization of SM or P. Mass spectrometry (MS), 
in turn, allows the generic detection of SM without labeling it. Instrumentation-wise, SEC is 
easily integrated with MS, and this combination has been extensively used to study proteins, 
antibodies, and peptides [108-110]. In KSEC-MS, the migration pattern of SM through the 
column depends on kon and koff. The rate constants can, thus, be deconvoluted from the temporal 
pattern of SM elution at the exit of the SEC column. 
Here, we present an implementation of KSEC-MS, in which short plugs of SM and P are 
injected sequentially into a SEC column without the need to premix P and SM outside the 
column. We call this implementation plug–plug KSEC-MS (ppKSEC-MS) in analogy with plug–
plug kinetic capillary electrophoresis [30, 111, 112]. Figure 5.1A depicts migration of the 
species in a SEC column. In the beginning, a short plug of SM is injected into the column 
followed by injection of a short plug of P, with a small volume of buffer in between, as a spacer, 
to prevent mixing during the injection. The chromatographic migration is immediately started 
after injecting P. The molecular size of P is much larger than that of the SM and thus P moves 
faster than the SM. The P plug passes through the SM plug allowing for P to bind SM and form 
P–SM, which has a molecular size similar to that of P and thus comigrates with P. When the 
P/P–SM plug overtakes the SM plug, P–SM starts dissociating into P and SM. The latter is 
continuously separated from P and P–SM creating a trail of SM behind the P/P–SM plug. The 
resulting migration pattern is the following. The zone containing P and intact P–SM migrates 
first. The zone of SM that has not bound P (during the passage of the P plug through the SM 
plug) migrates the last. The trail of SM that dissociated from P–SM lies between these two 
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zones. Figure 5.1B schematically illustrates the detection step. P and P–SM elute first followed 
by SM that dissociated from P–SM and finally by SM that has not bound P. The eluate is 
sampled into an MS ionization source; the typical ionization methods are atmospheric-pressure 
chemical ionization (APCI) and electrospray ionization (ESI). The ionized SM is fragmented and 
detected by MS/MS, which offers high specificity and signal-to-noise ratio. All intact complexes 
are destroyed during the ionization so that SM is released from P–SM and also quantitated by 
MS/MS. In general, the time-dependence of signal from SM (a chromatogram) contains three 
features merging into one another: (i) a peak corresponding to SM originating from the decay of 
P–SM during ionization, (ii) a peak of SM that has not bound P, and (iii) a “bridge” between the 
two peaks that corresponds to SM that dissociated from P–SM during migration in a column 
(Figure 5.1B). The shape of the chromatogram is defined by kon and koff so that, in the final step 
of analysis, their values are found by fitting the experimental chromatogram with a computer-
simulated one while varying kon and koff (Figure 5.1C). The best fit of a single chromatogram 
reveals the values of kon and koff. 
To experimentally prove the suggested concept of ppKSEC-MS, we used carbonic 
anhydrase II (CAII) as P and acetazolamide (ACZ) as SM. CAII catalyzes the interconversion 
between carbon dioxide and bicarbonate, which is a critical reaction in regulating cellular 
respiration [113]; ACZ is a known CAII inhibitor [114]. A series of ppKSEC-MS experiments 
were performed at constant [SM] but varying [P]. The resulting chromatograms are shown by red 
traces in Figure 5.2. The general shape of the chromatograms corresponds to the expected one 
with two peaks and a bridge between them (Figure 5.1B). Increasing [P] led to an anticipated 
increase of both the leftmost peak, corresponding to intact P–SM eluting from the column, and 
the bridge, corresponding to SM dissociated from P–SM during its migration through the 
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column. At the same time, the rightmost peak, which corresponds to SM that had not bound P, 
predictably decreased with increasing [P]. The integral area under the chromatogram, which is 
proportional to the total amount of SM exiting the column, did not change with increasing [P]. 
This finding indicates that the P–SM was completely destroyed during the ionization process 
(which was desirable) and that all SM was accounted for. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. Conceptual depiction of ppKSEC-MS. Please see text for details. 
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5.2. Materials and Methods 
 
5.2.1. Chemicals and Materials 
Bio SEC-3 Size exclusion chromatography (SEC) columns were purchased from Agilent 
(Mississauga, ON, Canada). Carbonic anhydrase II (CAII), acetazolamide (ACZ) and were 
purchased from Sigma-Aldrich (Oakville, ON, Canada). All reagents were dissolved in 30 mM 
ammonium formate, pH 7.2. All other reagents were purchased from Sigma-Aldrich (Oakville, 
ON, Canada). All solutions were made using deionised water filtered through a 0.22 µm filter 
(Millipore, Nepan, ON, Canada). 
 
5.2.2. Instrumentation  
The Shimadzu UFLCXR with Agilent Bio SEC-3 was used for all experiments. The 
column has 3 µm particle size, 100 Å pore size, 4.6 mm inner diameter and 300 mm length. The 
AB Sciex QTRAP 6500 with IonDrive Turbo V Source (Concord, ON, Canada) was used for 
small molecule detection and quantification. Isothermal titration calorimetry (ITC) experiments 
were performed by using a MicroCal iTC200 system (Northampton, MA, USA). 
 
5.2.3. Plug-plug KSEC with MS detection  
The 30 mM ammonium formate, pH 7.2 was used for all sample preparation and 
separation. An HPLC instrument does not allow multiple injections, therefore, the plug-plug 
setup was realized by combing two consecutive runs. The first run started with an injection of 10 
µL of ACZ, followed by a 2-min long separation with a flow rate of 0.3 mL/min. The second run 
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began immediately after the first run with an injection of 10 µL of CAII, followed by a 20-min 
long separation with a flow rate of 0.3 mL/min. Atmospheric-pressure chemical ionization 
(APCI) was used to ionize ACZ with negative ion mode. The source temperature (TEM) was 
300°C, the ionization energy (IS) was -4,500 V, and the de-clustering potential (DP) was -125 V. 
The MRM mode was used to select the ion of 221/83 (Q1/Q3) by using the collision energy (CE) 
at of -30 V. All binding experiments were done in triplicates. Fitting the experimental ppKSEC-
MS chromatograms with the simulated ones was carried out by using COMSOL Multiphysics 
4.3a commercial software (COMSOL Group, Palo Alto, CA). 
 
5.2.4. Isothermal titration calorimetry analysis.  
All samples were prepared in 30 mM ammonium formate, pH 7.2. Binding experiments 
were conducted using 10 µM CAII and 100 µM ACZ at 25°C. The experimental setup consisted 
of 19 successive 2 µL injections of either ACZ or buffer into CAII every 180 s to a final molar 
ratio of 2:1. The first injection was 0.2 µL for all experiments. The data were corrected for the 
heat of dilution of the titrant. Data analysis was carried out with Origin 5.0 software 
 
5.3. Results and Discussion 
The values of kon and koff are convoluted into the shape of chromatograms. An analytical 
solution for their deconvolution does not exist, leaving us with a single option: numerical 
solution of an inverse problem. In essence, an experimental chromatogram should be fitted with 
a simulated chromatogram computed using a 1-dimensional mathematical model describing both 
equation 5-1 and mass transfer in a SEC column. 
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There are many theoretical works on the separation of polymers by SEC that consider the 
thermodynamics of distribution of polymer fractions between the mobile and stationary phases 
[115-120]. They mainly study separation principles and often use fairly complicated mathematics 
and detailed process descriptions. Two-dimensional hydrodynamic models have also been 
suggested to describe SEC columns [121-123]. These models employ additional differential 
equations to take into account diffusion of solutes within the bead pores. On the other hand, a 
simple one-dimensional hydrodynamic model can be used in our case if this model takes into 
account the basic features of the described experiments (Figure 5.1). 
We developed such a model in which a long and narrow cylindrical chromatography 
column is coaxial with the x coordinate. A SEC column is packed with beads that have pores; the 
solution inside the pores constitutes the stationary phase. We assume that the pores are large 
enough for SM to enter and reside inside for a significant time and too small for the protein or 
the protein–small molecule complex to penetrate and be significantly retarded. This is a typical 
assumption that is confirmed by a significant difference in retention times between SM and P–
SM (Figure 5.2). We also assume fast re-equilibration between the mobile phase (solution 
outside the beads) and stationary phase. This is also a typical assumption that is confirmed by 
narrowness of peaks of P–SM and SM in Figure 5.2.  
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Figure 5.2. Experimental (red) and simulated (blue) ppKSEC-MS chromatograms for kinetic 
analysis of reversible binding between CAII and ACZ. The concentration of ACZ was 20 µM, 
and the concentration of CAII varied from 4 µM (A) to 80 µM (E). The control (F) 
corresponds to a run with a zero concentration of CAII. The ACZ signal was recorded in 
negative MRM mode for 221/83 (Q1/Q3) m/z. Simulated chromatograms were generated 
from modeling the processes involved in ppKSEC by using COMSOL multiphysics software. 
The binding parameters were determined from the best fit of the experimental chromatogram 
by the simulated one and were calculated on the basis of the averages and standard deviations 
of results obtained in triplicates. 	  	  
In ppKSEC-MS, a short plug of SM is injected followed by injection of a considerably longer 
buffer spacer and finally a short plug of P. The injection times, τ, for SM and P are short and 
equal while the injection time, tspc, for the spacer is much longer, tspc ≫ τ, thus eliminating the 
possibility of mixing between SM and P prior to the start of separation. Since P cannot enter the 
pores, equation 5-1 can only proceed outside the beads in the so-called free volume. In addition, 
a hydrodynamic flow of the solution exists only outside the beads. Therefore, we assume that the 
buffer velocity as well as [P] and [P–SM] are averaged across the column over the area lying 
outside the beads. Moreover, [SM] outside the beads and inside the beads are averaged across the 
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column over the total area lying outside the beads and inside the pores. Interactions between the 
species and their mass transfer are described by the following equations: 
 2SM SM off on( )[SM] ( [P-SM] [SM][P])t x xv D k kα∂ + ∂ − ∂ = −   (5-2) 
2
P off on( )[P] [P-SM] [SM][P]t x xv D k k∂ + ∂ − ∂ = −   (5-3) 
2
P on off( )[P-SM] [SM][P] [P-SM]t x xv D k k∂ + ∂ − ∂ = −     (5-4) 
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2 2 2
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  (5-5) 
Here, v is the average velocity of the hydrodynamic flow in the column; vSM is the average 
velocity of SM in the column; Dout and Din are diffusion coefficients of SM outside the beads and 
inside their pores, respectively; DP is the diffusion coefficient of P and P–SM (we consider it to 
be the same as SM binding P does not significantly affect the molecular size of P); ϕout and ϕin 
are relative volumes (i.e., fractions of the column volume) located outside beads and inside 
pores, respectively; k ∼ Din/Rin2 is the kinetic rate constant for a diffusion relaxation between 
concentrations of small molecules outside the beads and inside their pores; Rin is the 
characteristic size of beads. The average concentrations of SM outside the beads, [SM]out, and 
inside the pores, [SM]in, can be considered to be similar due to fast diffusion equilibration 
between the pores and the outside-the-beads volume ([SM]out = [SM]in = [SM]). Indeed, for a 
characteristic time, tin, of the diffusion relaxation between SM outside the beads and inside their 
pores, we have tin ∼ Rin2/Din ∼ 0.01 s for typical values of Rin ∼ 3 µm and Din ∼ 10–5 cm2/s. Thus, 
tin ≪ tsep = W/(v – vSM), where tsep is the separation time which is usually in the order of a few 
seconds (W is the plug length). It should be noted that a coefficient α depends only on the ratio 
ϕout/ϕin that coincides with the ratio of actual (not relative) volumes located outside beads and 
inside pores. 
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In ppKSEC-MS, nonequilibrium boundary conditions at x = 0 were used. Such boundary 
conditions for equation 5-2 to equation 5-5 can be formulated as follows: 
[SM]= [SM]0 (x = 0, 0 < t < ! )
[P]= [P]0 (x = 0, tspc < t < tspc +! )
     (5-6) 
where [SM]0 and [P]0 are initial concentrations of SM and P injected in the column inlet, τ is the 
injection time of SM and P, and tspc is the time interval between injections of SM and P. 
Concentrations at x = 0 are assumed to be zero for other time intervals. Equation 5-2 to equation 
5-6were used to obtain a numerical solution of the problem and to simulate signal S(t) generated 
by SM. We assume that all intact P–SM that reaches the end of the column dissociates during 
ionization and SM released from this dissociation is detected. As a result, S(t) is proportional to 
the total concentration of SM (both unbound and bound to P) at the column exit and g is a 
proportionality coefficient: 
( ) ( ) ( )( )[SM] [P-SM]S t g t t= +       (5-7) 
The described model was implemented in COMSOL Multiphysics 4.3a (commercial software). 
The Transport of Diluted Species module of COMSOL was used in simulations of equation 5-2 
to equation 5-6. The program generated simulated ppKSEC-MS chromatograms, S(t). Nonlinear 
regression was used to find best fits of the experimental ppKSEC-MS chromatograms (red 
traces) by the simulated ones (blue traces) while varying the values of kon and koff (Figure 5-2). It 
should be noted that parameters vSM, DSM, and g can be determined by fitting the experimental 
chromatogram obtained for injecting SM alone (i.e., in the absence of the protein). Similarly, 
parameters v and DP can be found by fitting the experimental chromatogram obtained for 
injecting P without SM. Provided that vSM and v are determined, parameter α can be calculated 
using the first relation in equation 5-5. As a result, only parameters kon and koff have to be varied 
	  	  
	  92 
in the fitting procedure involving experimental ppKSEC-MS data obtained for injecting both SM 
and P. 
We varied the concentration of the protein to test if the solutions for kon and koff were 
stable. When the protein concentration increased 20-fold, the values of kon and koff remained 
stable: kon = (15.4 ± 2.2) × 104 M–1 s–1 and koff = (17.8 ± 2.0) × 10–3 s–1 (rules of error 
propagation were used to find the errors of kon and koff). There was a noticeable trend of 
monotonic increase in kon and less monotonic increase in koff. This trend indicates that there is a 
small systematic error in the calculations. The error is most likely due to some minor phenomena 
in the separation and/or molecular interactions that are not taken into account by the simple 
mathematical model used to fit the experimental chromatograms. The value of the equilibrium 
dissociation constant was calculated as koff/kon: Kd = (117 ± 16) × 10–9 M. To validate our results, 
we used another solution-based label-free method, isothermal titration calorimetry (ITC). ITC 
can only determine Kd, but we used this validation method since there is no other label-free 
kinetic method available for such a validation. ITC experiments revealed Kd = (76 ± 5) × 10–9 M 
(Figure 5.3). Kd values obtained with ppKSEC-MS (∼120 nM) and ITC (∼80 nM) are in 
reasonable agreement considering that the temperatures in the ppKSEC-MS and ITC are difficult 
to make equal and conceptually different methods can lead to up to several-fold differences in 
measured equilibrium constants [124]. This agreement indicates that Kd calculated as koff/kon for 
kon and koff obtained with ppKSEC-MS is correct. Even though there is still a possibility that kon 
and koff were determined with a similar systematic error, which was canceled upon division of 
koff over kon, such an error appears to be extremely unlikely. Therefore, we can conclude that 
ppKSEC-MS correctly determined kon and koff for reversible binding of CAII and ACZ. 
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Figure 5.3. Thermograms of binding analysis between CAII and ACZ by ITC. Panel (A) 
corresponds to titrating CAII with ACZ while panel (B) corresponds to titrating CAII with 
buffer only. The upper graphs show the raw ITC data in real time, and the lower graphs show 
the corresponding integrated total heat per injection with respect to molar ratio. The fitting 
was generated by using Origin software with a single-binding-site model. 
 
5.4. Conclusions 
In conclusion, we outline major features of ppKSEC-MS in application to kinetic studies of 
protein–small molecule interactions. The method relies on generic separates of SM and P–SM by 
SEC without immobilization and generic quantitative detection of SM by MS without labeling. 
Any pair of P and SM can be separated by SEC assuming that neither of the molecules adsorbs 
on the beads material. MS, in turn, can detect any small molecule assuming that suitable 
ionization conditions are found and the major ion products are known. Advantageously, 
ppKSEC-MS requires no detection of intact P–SM, which is a very challenging task [125]. 
Moreover, data processing becomes simpler if the intact P–SM completely dissociates during 
ionization, which is easy to achieve in APCI [126]. In addition, ppKSEC-MS is a kinetic method 
that does not require equilibrium to be reached in equation 5-1. As a result, [P]0 and [SM]0 that 
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significantly differ from Kd [30] can be used, thus relaxing the requirements for the limit of 
detection in MS [29, 127]. In ppKSEC-MS, SM and P are injected separately and reacted inside 
the column, thus minimizing sample consumption and making the process easily suitable for 
automation without the use of sophisticated liquid handlers.  
Overall, our results suggest that ppKSEC-MS has a potential to become a generic solution-
based label-free platform for kinetic studies of protein–small molecule interactions, but more 
detailed studies will be needed to understand the advantages and limitations of the method better. 
In general, a robust analytical platform should be applicable to various samples with different 
conditions. Therefore, in the next chapter, we will expand the team of KSEC and introduce 
another type of KSEC-MS analysis. The new method utilizes pre-equilibrated target-ligand 
binding mixture as the sample of injection, to verify the versatility of KSEC-MS as an analytical 
platform for secondary ligand screening.  
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CHAPTER 6. PRE-EQUILIBRATION KINETIC SIZE-
EXCLUSION CHROMATOGRAPHY WITH MASS 
SPECTROMETRY DETECTION (PEKSEC-MS) FOR LABEL-
FREE SOLUTION-BASED KINETIC ANALYSIS OF PROTEIN–
SMALL MOLECULE INTERACTIONS 
 
The presented material was published previously and reprinted with permission from “Bao, 
J., Krylova, S. M., Cherney, L. T., Le Blanc, J. C. Y., Pribil, P., Johnson, P. E., Wilson, D. J., & 
Krylov, S. N. (2015). Pre-equilibration kinetic size-exclusion chromatography with mass 
spectrometry detection (peKSEC-mS) for label-free solution-based kinetic analysis of protein–
small molecule interactions. The Analyst, 140(4), 990–994. doi:10.1039/c4an02232g” 
Reproduced by permission of The Royal Society of Chemistry. My contribution to the article 
was: (i) planning all experiments, (ii) synthesized the protein, (iii) performing all experiments, 
(iv) preparing figures, (v) writing the manuscript.  
 
6.1 Introduction 
In the previous study, we have successfully developed the first method of KSEC-MS, in 
which the small molecule and protein were sequentially injected, followed by the interactions 
during separation. Plug-plug KSEC-MS is the first generic label-free solution-based kinetic 
method for analyzing protein-small molecule interactions. However, for secondary ligand 
screening, the method of choice has to be versatile in analyzing various samples under different 
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conditions. Therefore, in this study, we will further develop the idea of KSEC and introduce the 
pre-equilibration kinetic size-exclusion chromatography mass spectrometry (peKSEC-MS). 
Recently we have introduced a solution-based, label-free approach for kinetic analysis of 
non-covalent protein–small molecule interactions called kinetic size-exclusion chromatography 
mass spectrometry (KSEC-MS) [42]. In a schematic sense, non-covalent protein-small molecule 
interactions can be illustrated in equation 6-1, which involves a protein (P), a small molecule 
(SM), and a protein-small molecule complex (P-SM): 
P+SM
k
on
k
off
! "!!# P-SM        (6-1) 
koff and kon are the kinetic rate constants of dissociation and association respectively. The 
equilibrium dissociation constant can be calculated through Kd = koff/kon (smaller Kd value 
indicates high affinity binding). In KSEC-MS, generic solution-based kinetic separation is 
realized in a size-exclusion chromatography (SEC) column; label-free detection of SM is done 
using tandem mass spectrometry (MS/MS). The shape of the resulting chromatogram, signal 
(proportional to SM concentration) versus time, is defined by kon and koff. The values of kon and 
koff can be determined by finding a suitable mathematical model and fitting the experimental 
chromatogram with simulated ones while varying kon and koff. The best fit reveals the appropriate 
values of kon and koff. Plug–plug kinetic size-exclusion chromatography mass spectrometry 
(ppKSEC-MS) was our first practical implementation of the KSEC-MS concept. In essence, 
short plugs of SM and P are separately injected into the column; SM is followed by P. In a SEC 
column, P moves faster, and during the plug of P passing through the plug of SM, the binding 
reaction occurs and the P–SM complex is formed. When P outruns SM, the continuous 
dissociation of the complex starts. We developed a 1-dimensional numerical model for 
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simulating a ppKSEC-MS chromatogram, and used it to find kon and koff for the interaction of 
carbonic anhydrase and its inhibitor, acetazolamide.  
To further develop the idea of label-free solution-based kinetic measurements, we now 
introduce the next KSEC-MS method, pre-equilibration kinetic size-exclusion chromatography 
(peKSEC). The concept of peKSEC is depicted in Figure 6.1. An “equilibrium mixture” (EM) is 
prepared by incubating P with SM to approach the equilibrium shown in equation 6-1. A small 
volume of the EM (much smaller than free volume of the column) is injected into a SEC column 
at time t0 and its components are separated based on their size differences. As soon as SM is 
separated from P–SM, the latter is no longer at equilibrium and starts dissociating releasing more 
unbound SM. The dissociation process continues leaving a “tail” of SM. The samples in the 
column will eventually elute in the following order: (i) the intact P–SM, (ii) the “tail” of SM that 
dissociated from the complex during separation, and (iii) the unbound SM in the EM. Upon 
leaving the column the small molecule can be ionized by various ionization methods, such as 
electrospray ionization (ESI) or atmospheric-pressure chemical ionization (APCI), and detected 
[128]. During ionization, the intact P–SM is deliberately destroyed, thus SM from the complex is 
released and also detected by MS/MS. In general, a peKSEC-MS chromatogram contains 3 
features: (i) a peak that corresponds to SM that exited the column as a part of the intact P–SM, 
(ii) a peak of SM that was unbound in EM, and (iii) a bridge between the two peaks that 
corresponds to SM that was bound to P but dissociated during separation. The shapes and areas 
of these three features are defined by kon and koff. Accordingly, fitting the chromatogram with a 
1-dimensional mathematical model that describes reaction 1 along with mass transfer in the 
chromatographic column reveals both rate constants kon and koff.  
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Figure 6.1. Conceptual depiction of separation (a), detection (b), and data processing (c) in 
peKSEC.  Please see text for details. 	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6.2 Materials and Methods 
 
6.2.1 Chemicals and Materials 
Methotrexate (MTX) was purchased from Sigma-Aldrich (Oakville, ON, Canada). The E. 
coli Rossetta-gamiTM 2(DE3) competent cells was purchased from EMD Millipore (PA, USA). 
Sepharose Fast Flow column, Phenyl Sepharose 6 Fast Flow column and Sephacryl S-100 size 
exclusion column were purchased from GE Healthcare (Toronto, ON, Canada). The 30,000 MW 
cutoff Amicon® Ultra 15 mL centrifugal filter devices were purchased from EMD Millipore 
(Nepan, ON, Canada). All other reagents were purchased from Sigma-Aldrich (Oakville, ON, 
Canada). All solutions were made using deionised water filtered through a 0.22 µm filter 
(Millipore, Nepan, ON, Canada). 
 
6.2.2 Protein expression and purification.  
The plasmid pFW117.1 that contains folA (E. coli DHFR) gene was transformed into the 
competent E. coli Rossetta-gamiTM 2 (DE3) cells. 1L bacterial culture was growing at 37°C, 260 
rpm shaking until the OD600 reached 0.8. The culture was then induced with 1.0 mM IPTG and 
continues growing at 20°C, with 260 rpm shaking overnight. After induction, the cells were 
collected by centrifugation at 5500 rpm for 1 hour at 4°C. The cell pellet was resuspended in 20 
mM Tris-HCl pH 6.2, 0.5 mM EDTA, 0.5 mM DTT , 0.02 % NaN3 w/v (buffer A), and then 
sonicated on ice with 15 s on and 55 s off intervals for 4 min at 60 % amplitude. The lysate was 
centrifuged at 5500 rpm for 1 hour at 4°C and the supernatant containing DHFR was loaded onto 
the Q Sepharose Fast Flow column previously equilibrated with buffer A. The DHFR elution 
was achieved by using a NaCl gradient from 0 to 1.0 M in buffer A, and DHFR eluted at 
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concentrations of 0.4 M NaCl. The fractions containing DHFR were concentrated and dialyzed 
against 50 mM sodium phosphate pH 7.0 and 1.0 M (NH4)2SO4 , 0.02 % NaN3 w/v (buffer B). 
The DHFR containing solution was then loaded onto the Phenyl Sepharose 6 Fast Flow column, 
which was pre-equilibrated with buffer B. The DHFR elution was achieved using 1.0 to 0 M 
(NH4)2SO4 gradient in buffer B, and DHFR eluted at 0.5 M (NH4)2SO4. The fractions containing 
DHFR were concentrated and dialyzed with 100 mM sodium phosphate pH 7.0, 150 mM NaCl, 
0.5 mM EDTA, 0.02 % NaN3 w/v (buffer C), and then loaded onto a Sephacryl S-100 size 
exclusion column. All buffer flow rates were 1 mL/min on an ÄKTA-FPLC system. The purified 
DHFR was dialyzed against 30 mM ammonium formate pH 7.2 (buffer D) 
 
6.2.3 Instrumentation  
The Allegra 21R centrifuge with S4180 rotor was purchased from Beckman Coulter (ON, 
Canada). ÄKTA-FPLC system was purchased from GE Healthcare (Toronto, ON, Canada). The 
Shimadzu UFLCXR with Agilent Bio SEC-3 was used for all experiments. Bio SEC-3 Size 
exclusion chromatography (SEC) column was purchased from Agilent (Mississauga, ON, 
Canada). The column has 3 µm particle size, 150 Å pore size, 4.6 mm inner diameter and 300 
mm length. The AB Sciex QTRAP 6500 with IonDrive Turbo V Source (Concord, ON, Canada) 
was used for small molecule detection and quantification. Isothermal titration calorimetry (ITC) 
experiments were performed by using a MicroCal iTC200 system (Northampton, MA, USA). 
 
6.2.4 Pre-equilibration KSEC with MS detection.  
Buffer D was used for all sample preparation and separation. The pre-equilibration binding 
mixture was made by incubating 20 nM MTX with different concentrations of DHFR (20 nM – 
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80 nM) for 10 min at 20°C. 10 µl of binding mixture was injected in to HPLC and separation 
was conducted at a flow rate of 0.3 mL/min 20°C. Atmospheric-pressure chemical ionization 
(APCI) was used to ionize MTX with positive ion mode. The source temperature (TEM) was 
300°C, the ionization energy (IS) was 5,500 V, and the de-clustering potential (DP) was 125 V. 
The MRM mode was used to select the ion of 445.2/308.2 (Q1/Q3) by using the collision energy 
(CE) at of 28 V. All binding experiments were done in triplicates. Fitting the experimental 
peKSEC-MS chromatograms with the simulated ones was carried out by using COMSOL 
Multiphysics 4.3a commercial software (COMSOL Group, Palo Alto, CA). 
 
6.2.5 Isothermal titration calorimetry analysis.  
Buffer D was used for all experiments. Binding experiments were conducted using 10 µM 
DHFR and 100 µM MTX at 25°C. The experimental setup consisted of 19 successive 2 µL 
injections of either MTX or buffers into DHFR every 180 s to a final molar ratio of 1:2. The first 
injection was 0.2 µL for all experiments. The data were corrected for the heat of dilution of the 
titrant. Data analysis was carried out with Origin 5.0 software. 
 
6.3 Results and Discussion 
The great strength of peKSEC-MS is that it relies on a generic separation as a small 
molecule can always be separated from a large P–SM complex. Moreover, peKSEC-MS uses a 
generic detection scheme, as practically any small molecule can be selectively detected by 
MS/MS. Here, we chose the interaction between dihydrofolate reductase (DHFR) and 
methotrexate (MTX) as a model system. DHFR is an essential enzyme in cell proliferation and 
cell growth; it converts dihydrofolic acid to tetrahydrofolic acid, and MTX is its well-known 
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inhibitor [23, 129, 130]. DHFR and MTX can be easily separated by SEC based on the 
difference in their sizes. The MS/MS signal intensity of MTX was proportional to the 
concentration in a range of 10 µM–100 pM; the linear response in the nanomolar range is 
essential for studying high affinity binding (nanomolar Kd). When EM of DHFR and MTX was 
sampled for detection of MTX, only a predicted peKSEC-MS chromatogram was obtained in 
Figure 6.2. The signal intensity of the leftmost peak, which corresponds to P–SM increased with 
increasing protein concentration [P] in EM. A similar trend was also observed for the bridge 
region, which corresponds to SM that dissociated from P–SM during separation. Meanwhile, as 
we anticipated, the rightmost peak, free SM, decreased with increasing [P] in EM. The integral 
of the SM signal over the entire chromatogram remained constant with changing [P] (and the 
concentration of small molecule [SM] remained constant) suggesting that the intact complex was 
completely dissociated and all SM was accounted for. 
Deconvolution of the kinetic rate constants from a peKSEC-MS chromatogram is not a 
trivial task. While no analytical solutions are available, we have adapted the numerical approach 
previously developed for modeling ppKSEC-MS to model processes in peKSEC-MS. It is a 1-
dimensional model that considers complex dissociation and complex re-formation during 
migration of the components through the column. The following setup is used for the 1-
dimensional approach in peKSEC-MS. A long and narrow cylindrical chromatography column is 
used, which is coaxial with the x coordinate. It is filled with beads that constitute the stationary 
phase. The beads have pores, which are, in the first approximation, large enough for the SM to 
enter and reside inside for a significant time and too small for the P or the P–SM to be 
significantly retarded. This is confirmed by the significant difference in retention times between 
SM and P–SM. Also, the model uses an assumption of fast re-equilibration between the mobile 
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and stationary phase, which is confirmed by narrow peaks of P and SM. An EM plug containing 
SM, P, and P–SM is injected into the column at t = 0 (t0). We assume that the buffer velocity and 
concentrations of components P and P–SM are averaged across the column over the area lying 
outside the beads. Similarly, the concentrations of SM outside the beads and inside them are 
averaged across the column over the area lying outside the beads and inside the pores, 
respectively. Mass transfers of SM, P, and P–SM are described by the following equations: 
(!t +vA!x "DA!x
2 )[SM]=!(koff [P-SM]" kon[SM][P])     (6-2) 
(!t +v!x "DP!x
2 )[P]= koff [P-SM]" kon[SM][P]     (6-3) 
 (!t +v!x "DP!x
2 )[P-SM]= kon[SM][P]" koff [P-SM]     (6-4) 
 vA =!v , ! =
"out
"out +"in
, DA =
!outDout +!inDin
!out +!in
    (6-5) 
Here, [SM], [P], and [P–SM] are the concentrations of the small molecule, protein, and the 
complex, respectively; v is the average velocity of the buffer; Dout and Din are diffusion 
coefficients of SM outside the beads and inside their pores; DP is the diffusion coefficient of P 
and P–SM (we consider them similar since SM does not significantly affect the size of P upon 
binding); ϕout and ϕin are relative volumes (i.e. fractions of the column volume) located outside 
beads and inside pores, respectively. Average concentrations of SM outside beads and inside 
pores are considered to be approximately the same due to fast diffusion equilibration between 
pores and outside the bead volume. Indeed, we usually have tin ∼ Rin2/Din where tin is the 
characteristic time of diffusional relaxation between concentrations of small molecules outside 
the beads and inside their pores and Rin is the characteristic size of the beads. The relationship tin 
∼ Rin2/Din follows from the fact that Einstein's characteristic diffusion length (Dint)1/2 should be of 
the order of the characteristic size of beads, Rin, if we calculate this length for the characteristic 
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time of diffusional relaxation t ∼ tin. At Rin ∼ 3 µm and Din ∼ 10−5 cm2 s−1 calculations give tin ∼ 
0.01 s. Thus tin ≪ tsep = W/(v − vA) where tsep is the separation time which is usually on the order 
of a few seconds and W is the plug length. It should be noted that coefficient α depends only on 
the ratio ϕout/ϕin that coincides with the ratio of actual (not relative) volumes located outside 
beads and inside pores. We have also omitted an additional term proportional to tin [42] in the 
last equation (6-5) for DSM since we used the fitting procedure to determine DSM. 
To formulate initial conditions from equation 6-2 to equation 6-5 take into account that the 
injection usually satisfies the following conditions: (i) the mixture of SM, P, and P–SM is in 
equilibrium before the injection; (ii) tinj ≪ teq, where tinj is the injection time and teq = 1/(kon[P]0 + 
koff) is the equilibration time; and (iii) tin ≪ tinj. In this case, the concentrations in the injected 
plug at t = 0 (i.e. immediately after injection) are determined by the following relations: 
[SM]0 =![SM]eq , [P]0 = [P]eq , [P-SM]0 = [P-SM]eq
(0 ! x !W , t = 0)
  (6-6) 
W =
V inj
!"outR
2
, !out =
Vfree
!R 2L
      (6-7) 
Here, [SM]eq, [P]eq, and [P–SM]eq are concentrations of SM, P, and P–SM in their equilibrium 
mixture before injection; W is the plug length after injection; Vinj is the volume of injected 
mixture; Vfree is the free column volume measured by elution of the protein (in the absence of 
small molecules); R is the inner radius of the column; and L is the column length. Equation 6-2 
to equation 6-7 were used to obtain a numerical solution of the problem and to simulate signal 
S(t) generated by SM. We assume that the intact P–SM that reaches the end of the column 
dissociates in the mass-spectrometer and SM produced from this dissociation can be detected. As 
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a result S(t) is proportional to the total concentration of SM (both unbound and bound to P) at the 
column exit, where g is a proportionality coefficient: 
S (t ) = g ([SM](t )+[P-SM](t ))       (6-8) 
The model was implemented using COMSOL multi-physics software (4.3a commercial 
software). The kinetic rate constants kon and koff were convoluted to form a simulated 
chromatogram. Non-linear regression was used to find the best fit of the experimental peKSEC-
MS chromatogram with the simulated one. By fitting the experimental chromatograph to the 1-
dimensional model we have calculated the kinetic rate constants: kon = (57.2 ± 3.5) × 104 M−1 s−1, 
koff = (47.2 ± 4.6) × 10−4 s−1, and Kd = (8.2 ± 1.3) × 10−9 M through koff/kon. The best fits for 
different chromatograms (Figure 6.2) returned similar values of kon and koff suggesting that the 
solution is stable and also allowing us to estimate the method's precision. To validate our results, 
we chose another label free solution based method ITC (Figure 6.3). ITC is an equilibrium 
method from which only Kd can be calculated [131]; it was selected due to the lack of other 
label-free kinetic methods. ITC and peKSEC-MS are conceptually different methods, offering a 
means of validation with higher stringency. The ITC measured equilibrium dissociation constant 
Kd = (10.2 ± 0.8) × 10−9 M, which agreed with peKSEC-MS measured results within acceptable 
errors, confirmed the accuracy of peKSEC-MS. 
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Figure 6.2. The peKSEC analysis of DHFR-MTX binding interactions. There are 20 nM 
MTX mixed with different concentrations of DHFR (a) to (c). The control (d) contains MTX 
only. The MTX signal was detected with MS/MS for 455.2/308.2 (Q1/Q3) m/z. Simulation 
chromatograms (blue) were generated from modeling the processes involved in peKSEC by 
using COMSOL multi-physics software. The kinetic rate constants were determined from the 
best fit of the experimental chromatogram (red) by the simulated one, and were calculated 
based on the average and standard deviation of triplicated results. 
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Figure 6.3. Thermograms of binding analysis between DHFR and MTX by ITC. (a): titrating 
DHFR with MTX and (b): titrating DHFR with buffer only. The upper graphs show the raw 
ITC data in real time and the lower graphs show the corresponding integrated total heat per 
injection with respect to molar ratio. The fitting was generated by using Origin 5.0 software 
with a single-binding-site model.   
 
6.4 Conclusions 
To conclude, we have outlined the main features of peKSEC-MS, which is a label-free 
solution-based method for studying the kinetics of reversible binding between a protein and a 
small molecule. In peKSEC, the migration pattern of the small molecule through a SEC column 
is followed by MS detection, and the kinetic parameters are extracted from the MS signal versus 
time dependence by means of numerical modelling. The numerical model uses two assumptions: 
(i) complex dissociation is complete during the ionization and (ii) the ionization efficiency of 
small molecules remains constant. In essence, we assume that the linear response of MS to small 
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molecule concentration is retained throughout the analysis. The requirement of complete 
dissociation is easily satisfied, as it is difficult to keep non-covalent complexes intact during the 
ionization process. The second assumption may not be always satisfied; for example, the 
ionization efficiency of a small molecule could be affected when it co-elutes with the protein 
[132]. Therefore, it is essential to confirm the method's validity by comparing the integrated 
small molecule signals among all tests – it should remain constant for constant small molecule 
concentration and not depend on the concentration of the protein. Moreover, measuring fast 
reactions with low Kd values will require low concentrations of interacting molecules and 
accordingly lower detection limit of MS [29, 30, 41]. The sub-nanomolar Kd measurements will 
require a mass spectrometer with a sub-nanomolar detection limit. Instrumentation for peKSEC-
MS used in this study can measure small molecule concentration of 100 pM and the best 
contemporary MS instruments have limits of detection in the zeptamolar range [133]. 
Advantageously, peKSEC-MS does not require MS detection of an intact protein–small molecule 
complex, which may be very challenging. The ability of MS to rapidly scan through a wide mass 
range can potentially facilitate simultaneous analysis of one protein with several small molecules 
that potentially can be used for the rapid screening of panels of drug leads. The peKSEC method 
allows tight control of binding conditions such as incubation time and temperature, presence of 
cofactors, etc. Furthermore, as peKSEC relies on the established equilibrium prior to injection, 
we can now analyze the protein–small molecule interactions with slow association rates. 
Whereas in ppKSEC, the on-column incubation of a slow interacting pair is impractical, and it 
can also induce sample diffusion and peak broadening. We foresee that peKSEC-MS can become 
a generic solution-based label-free platform for kinetic studies of protein–small molecule 
interactions. 
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LIMITATIONS 
We have developed kinetic solution-based ligands selection methods: KCE-DEL and 
KSEC-MS. The primary screening involves KCE-DEL based selection, which focuses on the 
preliminary selection of all target binders. The secondary screening involves KSEC-MS, which 
is a label-free solution-based approach that focuses on evaluating the true kinetic binding 
parameters and ranking the potential ligands.  
For KCE-DEL based primary ligand screening, one of the most significant limitations is 
the contamination from synthetic intermediates. These synthetic intermediates have the very 
similar charge to size ratio and thus migrate very closely to the full ligand. Besides, these 
intermediates are all PCR amplifiable and thus can significantly affect the subsequent decoding 
procedure. Fortunately, the library of ligands can be purified before the primary screening. 
Although library purification leads to potential loss of ligands, the benefits from the elimination 
of contaminations far outweigh this disadvantage. 
Moreover, in KCE-DEL approach, the DNA tag provides means of ligand identification 
and also contributes to the electrophoretic mobility. However, as we discussed previously, any 
tag or label affects binding; therefore, the selected DEL may not truly reflect the interaction 
between the target and the ligand (without DNA tag). For example, on a microscopic level, only 
a particular portion of a ligand molecule participates in interaction with the binding site of a 
target protein; thus, a single DEL-target interaction cannot provide a whole picture of binding 
interactions. To overcome this, it is required to use a diversified library for ligand screening for 
discovery of all possible interacting fragments from the DEL library, and mapping an entire 
landscape for ligand-target interactions. Furthermore, there are also DEL molecules with 
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multiple ligands attached to a single DNA strand, which can be used to probe various binding 
sites of a protein target.    
For KSEC-MS based ligand selection, the major issue comes from the limit of detection 
(LOD) for ligands in MS. In general, high detection power allows searching for ligands with 
high target-binding affinity, which is often the most desirable property when selecting a potential 
drug molecule. Although each molecule has unique properties such as size and ionization 
efficiency that are contributing to the LOD, certain types of mass analyzers have higher detection 
power than others. Our current KSEC-MS methods were developed using triple quadruple mass 
analyzer, which has a LOD range about 10-10 to 10-11 M. This LOD range allows analyzing the 
target-ligand interactions with pM Kd. There are also more sensitive mass analyzers such as 
Fourier transform ion cyclotron resonance mass spectrometry (FTICR-MS) with zeptomole 
detection limit.  
Ideally, samples in KSEC should travel through the size-exclusion column without 
interacting with the solid phase. However, depending on the hydrophobicity, the small molecule 
can sometimes stick with certain types of column surfaces. Likewise, the non-specific surface 
adsorptions are also problematic in many other analytical techniques. Most target proteins, as 
well as protein-small molecule complexes, are typically not sticky in the size-exclusion columns. 
However since the profiles of small molecules are essential in determining kinetic binding 
parameters, it is crucial to find the appropriate column and optimize the separation conditions 
before KSEC-MS analysis. 
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CONCLUDING REMARKS 
The main attention in current pharmaceutical industry focuses on finding new drugs. 
Discovery of novel drug ligands significantly relies on screening methods. In general, the 
process of drug discovery involves primary and secondary screening steps. The existing primary 
screenings are mainly surface-based and inherently suffer from non-specific surface adsorption. 
Therefore, we developed a KCE based DEL selection, to overcome this issue. During the 
development of KCE-DEL, we built a model to accurately predict migration times of binding 
complexes with various DNA constructs that allow us to collected binding complex and select 
target-binding ligand. We have successfully demonstrated the efficiency and accuracy by using 
two proteins, SA and (CAII), and two ligands with tag structures identical to those in actual GSK 
libraries. Moreover, our model can be potentially used for other types of electrophoresis-based 
protein-DNA binding analysis.  
The secondary screening is conducted to investigate the binding parameters of target-
ligand interactions, and to rank ligands based on affinity and kinetic parameters. The existing 
methods are either surface-based kinetic methods or solution-based affinity methods, and neither 
of them was able to calculate the true kinetic binding parameters by definition. We have 
developed the first label-free solution-based kinetic platform, KSEC-MS, for analyzing target-
ligand interactions. Two types of methods, ppKSEC and peKSEC have been established and 
applied for assessing CAII-ACZ and DHFR-MTX binding interactions. They are also the first 
cases of calculating kinetic parameters kon and koff in a real label-free solution-based system. 
Furthermore, we were able to detect the binding affinity in the range of nM Kd. 
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To conclude, we have developed KCE-DEL and KSEC-MS for kinetic solution-based drug 
selections. We believe that in the very near future, our methods will emerge in the field of 
pharmaceutical discovery and facilitate as well as accelerate the therapies of many diseases. 
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FUTURE DIRECTIONS 
 UP until now, the proof of principle studies of KCE-DEL have been conducted and 
demonstrated as the solution-based approach for primary drug ligand screening. The next step 
will be developing KCE-DEL towards real ligand selection from the combinatorial libraries of 
DEL against therapeutic relevant protein targets. There are two potential problems that we may 
encounter when dealing with practical combinatorial libraries of DEL. First, the contaminations 
from synthetic intermediates will likely present in the library, which would interfere with the 
complex formations and subsequent PCR amplifications. Methods of CE are general separation 
approaches for DNA-based molecules and to solve such problem we can add a step of CE based 
DEL purification prior to the primary screening. Second, the binding conditions for many 
therapeutic relevant proteins require high salt conditions, which often trigger problems of high 
current and overheating during CE experiments. Therefore we need to find the proper 
combinations of salt concentrations, capillary dimensions, and the voltage supply, to support 
both target-ligand interactions and reliable CE separation. Also, we want to conduct KCE-based 
ligand selection in parallel with the conventional surface-based approach such as SPR, to 
compare the efficiencies and the systematic biases of both approaches, and also gain a in-depth 
understanding of these theoretically different analyses.  
KSEC is a novel concept that developed for generic separation between protein targets 
and small molecule ligands. Since KSEC-MS utilizes standard LC-MS system, it is ready to be 
used for ligand ranking in the pharmaceutical industry. The kinetic parameter calculations at the 
current stage require modeling of target-ligand binding interactions inside of SEC column, which 
is cumbersome to perform and also very time-consuming. Therefore, the next step will be 
developing a fast and straightforward analytical solution for kinetic analysis of KSEC-MS data. 
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Furthermore, we have analyzed target-ligand interactions with 1:1 binding ratio, meaning a 
single target bind to a single ligand. In future, we want to explore stoichiometric binding such as 
a single target protein molecule binds to multiple ligands (of the same type). Also, we are 
interested in testing the simultaneous interactions of a single target against multiple types of 
ligands to study the synergistic effect of different drug ligands. Additionally, we plan to develop 
a ppKSEC based in situ enzymatic reaction analysis, in which the enzymatic reactions are 
performed and monitored in-column. Finally, we want to exploit other types of MS analyzers 
such as FT-ICR, to study high-affinity target-ligand interactions. 
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